



(51) International Patent Classification:

C07H 1/00 (2006.01) *C12P 19/36* (2006.01)
C07H 15/256 (2006.01)

(21) International Application Number:

PCT/US2020/018460

(22) International Filing Date:

15 February 2020 (15.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/806,646 15 February 2019 (15.02.2019) US
62/823,381 25 March 2019 (25.03.2019) US


(71) Applicant: **PURECIRCLE USA INC.** [US/US]; 200 West Jackson Boulevard, Suite 800, Chicago, IL 60606 (US).(72) Inventors: **MARKOSYN, Avetik**; 8-27 Paruyr Sevak Street, Kanaker Zeytun, 0014 Yerevan (AM). **CHOW, Siew Yin**; No. 2, Lorong Limau Besar, Jalan, Meru, 41050 Klang, Selangor (MY). **NIZAM BIN NAWI, Khairul**;

No. 400, Lorong Nusari Aman 2/2C, Taman Nusari Aman 1, Bandar Sri Sendayan, 71950 Nilai, Negeri Sembilan (MY). **CHKHAN, Kristina**; Rublevskoe Shosse 38/2, 362, 121609 Moscow (RU). **AFZAAL BIN HASIM, Mo-hamad**; 7-15-6, Vista Angkasa, Bukit Kerinchi, 59200 Kuala Lumpur (MY). **RAMANDACH, Saravanan, A/L**; NO. 37, Jalan Seri Pandan 2, Taman Seri Pandan, 70400 Seremban, Negeri Sembilan (MY).

(74) Agent: **BABCOCK, Audrey, J.** et al.; Taft Stettinius & Hollister LLP, 2200 IDS Center, 80 South Eighth Street, Minneapolis, MN 55402 (US).(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: HIGH-PURITY STEVIOL GLYCOSIDES

FIG. 1a



(57) **Abstract:** Methods of preparing highly purified steviol glycosides. The methods include utilizing enzyme preparations and recombinant microorganisms for converting various starting compositions to target steviol glycosides. The highly purified steviol glycosides are useful as non-caloric sweetener, flavor enhancer, sweetness enhancer, and foaming suppressor in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums.



SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

HIGH-PURITY STEVIOL GLYCOSIDES

SEQUENCE LISTING

The text file entitled “PC_77WO_Final_ST25.txt,” created on April 10, 2018, having 15 kilobytes of data, and filed concurrently herewith, is hereby incorporated by reference in its entirety in this application.

TECHNICAL FIELD

The present invention relates to a process for preparing compositions comprising steviol glycosides, including highly purified steviol glycoside compositions.

BACKGROUND OF THE INVENTION

High intensity sweeteners possess a sweetness level that is many times greater than the sweetness level of sucrose. They are essentially non-caloric and are commonly used in diet and reduced-calorie products, including foods and beverages. High intensity sweeteners do not elicit a glycemic response, making them suitable for use in products targeted to diabetics and others interested in controlling for their intake of carbohydrates.

Steviol glycosides are a class of compounds found in the leaves of *Stevia rebaudiana* Bertoni, a perennial shrub of the *Asteraceae* (*Compositae*) family native to certain regions of South America. They are characterized structurally by a single base, steviol, differing by the presence of carbohydrate residues at positions C13 and C19. They accumulate in *Stevia* leaves, composing approximately 10% - 20% of the total dry weight. On a dry weight basis, the four major glycosides found in the leaves of *Stevia* typically include stevioside (9.1%), rebaudioside *A* (3.8%), rebaudioside *C* (0.6-1.0%) and dulcoside *A* (0.3%). Other known steviol glycosides include rebaudioside *B*, *C*, *D*, *E*, *F* and *M*, steviolbioside and rubusoside.

Although methods are known for preparing steviol glycosides from *Stevia rebaudiana*, many of these methods are unsuitable for use commercially.

Accordingly, there remains a need for simple, efficient, and economical methods for preparing compositions comprising steviol glycosides, including highly purified steviol glycoside compositions.

SUMMARY OF THE INVENTION

As used herein, the abbreviation term “reb” refers to “rebaudioside”. Both terms have the same meaning and may be used interchangeably.

As used herein, “biocatalysis” or “biocatalytic” refers to the use of natural or genetically engineered biocatalysts, such as enzymes, or cells comprising one or more enzyme, capable of single or multiple step chemical transformations on organic compounds. Biocatalysis processes include fermentation, biosynthesis, bioconversion and biotransformation processes. Both isolated enzymes, and whole-cell biocatalysis methods are known in the art. Biocatalyst protein enzymes can be naturally occurring or recombinant proteins.

As used herein, the term “steviol glycoside(s)” refers to a glycoside of steviol, including, but not limited to, naturally occurring steviol glycosides, e.g. steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s*, synthetic steviol glycosides, e.g. enzymatically glucosylated steviol glycosides and combinations thereof.

As used herein, the term “SvG7” refers to any naturally occurring steviol glycosides or any synthetic steviol glycosides, including enzymatically glucosylated steviol glycosides and combinations thereof, specifically a molecule comprising steviol having seven glucose residues attached covalently including, but not limited to reb *1a*, reb *1b*, reb *1c*, reb *1d*, reb *1e*, reb *1f*, reb *1g*, reb *1h*, reb *1i*, reb *1j*, reb *1k*, reb *1l*, reb *1m*, reb *1n*, reb *1o*, reb *1p*, reb *1q*, reb *1r*, reb *1s*, reb *1t*, reb *2a*, reb *2b*, reb *2c*, reb *2d*, reb *2e*, reb *2f*, reb *2g*, reb *2h*, reb *2i*, reb

2j, reb 2k, reb 2l, reb 2m, reb 2n, reb 2o, reb 2p, reb 2q, reb 2r, and/ or reb 2s. SvG7 can refer to a single steviol glycoside having seven glucose residues attached covalently or a mixture of steviol glycosides having seven glucose residues attached covalently.

The present invention provides a process for preparing a composition comprising a target steviol glycoside by contacting a starting composition comprising an organic substrate with a microbial cell and/or enzyme preparation, thereby producing a composition comprising a target steviol glycoside.

The starting composition can be any organic compound comprising at least one carbon atom. In one embodiment, the starting composition is selected from the group consisting of steviol glycosides, polyols or sugar alcohols, various carbohydrates.

The target steviol glycoside can be any steviol glycoside. In one embodiment, the target steviol glycoside is steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s*, SvG7 or a synthetic steviol glycoside.

In one embodiment, the target steviol glycoside is rebaudioside *1a*.

In one embodiment, the target steviol glycoside is rebaudioside *1b*.

In one embodiment, the target steviol glycoside is rebaudioside *1c*.

In one embodiment, the target steviol glycoside is rebaudioside *1d*.

In one embodiment, the target steviol glycoside is rebaudioside *1e*.

In one embodiment, the target steviol glycoside is rebaudioside *1f*.

In one embodiment, the target steviol glycoside is rebaudioside *1g*.

In one embodiment, the target steviol glycoside is rebaudioside *1h*.

In one embodiment, the target steviol glycoside is rebaudioside *1i*.

In one embodiment, the target steviol glycoside is rebaudioside *1j*.

In one embodiment, the target steviol glycoside is rebaudioside *1k*.

In one embodiment, the target steviol glycoside is rebaudioside *1l*.

In one embodiment, the target steviol glycoside is rebaudioside *1m*.

In one embodiment, the target steviol glycoside is rebaudioside *1n*.

In one embodiment, the target steviol glycoside is rebaudioside *1o*.

In one embodiment, the target steviol glycoside is rebaudioside *1p*.

In one embodiment, the target steviol glycoside is rebaudioside *1q*.

In one embodiment, the target steviol glycoside is rebaudioside *1r*.

In one embodiment, the target steviol glycoside is rebaudioside *1s*.

In one embodiment, the target steviol glycoside is rebaudioside *1t*.

In one embodiment, the target steviol glycoside is rebaudioside *2a*.

In one embodiment, the target steviol glycoside is rebaudioside *2b*.

In one embodiment, the target steviol glycoside is rebaudioside *2c*.

In one embodiment, the target steviol glycoside is rebaudioside *2d*.

In one embodiment, the target steviol glycoside is rebaudioside *2e*.

In one embodiment, the target steviol glycoside is rebaudioside *2f*.

In one embodiment, the target steviol glycoside is rebaudioside *2g*.

In one embodiment, the target steviol glycoside is rebaudioside *2h*.

In one embodiment, the target steviol glycoside is rebaudioside *2i*.

In one embodiment, the target steviol glycoside is rebaudioside *2j*.

In one embodiment, the target steviol glycoside is rebaudioside *2k*.

In one embodiment, the target steviol glycoside is rebaudioside *2l*.

In one embodiment, the target steviol glycoside is rebaudioside *2m*.

In one embodiment, the target steviol glycoside is rebaudioside *2n*.

In one embodiment, the target steviol glycoside is rebaudioside *2o*.

In one embodiment, the target steviol glycoside is rebaudioside *2p*.

In one embodiment, the target steviol glycoside is rebaudioside *2q*.

In one embodiment, the target steviol glycoside is rebaudioside *2r*.

In one embodiment, the target steviol glycoside is rebaudioside *2s*.

In one embodiment, the target steviol glycoside is rebaudioside *M4*.

In one embodiment, the target steviol glycoside is rebaudioside *M5*.

In one embodiment, the target steviol glycoside is SvG7.

In some preferred embodiments enzyme preparation comprising one or more enzymes, or a microbial cell comprising one or more enzymes, capable of converting the starting composition to target steviol glycosides are used. The enzyme can be located on the surface and/or inside the cell. The enzyme preparation can be provided in the form of a whole cell suspension, a crude lysate or as purified enzyme(s). The enzyme preparation can be in free form or immobilized to a solid support made from inorganic or organic materials.

In some embodiments, a microbial cell comprises the necessary enzymes and genes encoding thereof for converting the starting composition to target steviol glycosides.

Accordingly, the present invention also provides a process for preparing a composition comprising a target steviol glycoside by contacting a starting composition comprising an organic substrate with a microbial cell comprising at least one enzyme capable of converting the starting composition to target steviol glycosides, thereby producing a medium comprising at least one target steviol glycoside.

The enzymes necessary for converting the starting composition to target steviol glycosides include the steviol biosynthesis enzymes, NDP-glucosyltransferases (NGTs), ADP-glucosyltransferases (AGTs), CDP-glucosyltransferases (CGTs), GDP-glucosyltransferases (GGTs), TDP-glucosyltransferases (TDPs), UDP-glucosyltransferases (UGTs) and/or NDP-recycling enzyme, ADP-recycling enzyme, CDP-recycling enzyme, GDP-recycling enzyme, TDP-recycling enzyme, and/or UDP-recycling enzyme.

In one embodiment, the steviol biosynthesis enzymes include mevalonate (MVA) pathway enzymes.

In another embodiment, the steviol biosynthesis enzymes include non-mevalonate 2-C-methyl-D-erythritol-4-phosphate pathway (MEP/DOXP) enzymes.

In one embodiment the steviol biosynthesis enzymes are selected from the group including geranylgeranyl diphosphate synthase, copalyl diphosphate synthase, kaurene synthase, kaurene oxidase, kaurenoic acid 13-hydroxylase (KAH), steviol synthetase, deoxyxylulose 5-phosphate synthase (DXS), D-1-deoxyxylulose 5-phosphate reductoisomerase (DXR), 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase (CMS), 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (CMK), 4-diphosphocytidyl-2-C-methyl-D-erythritol 2,4- cyclodiphosphate synthase (MCS), 1-hydroxy-2-methyl-2(E)-butenyl 4-diphosphate synthase (HDS), 1-hydroxy-2-methyl-2(E)-butenyl 4-diphosphate reductase (HDR), acetoacetyl-CoA thiolase, truncated HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, mevalonate pyrophosphate decarboxylase, cytochrome P450 reductase etc.

The UDP-glucosyltransferase can be any UDP-glucosyltransferase capable of adding at least one glucose unit to steviol and/or a steviol glycoside substrate to provide the target steviol glycoside.

As used hereinafter, the term “SuSy_AT”, unless specified otherwise, refers to sucrose synthase having amino-acid sequence “SEQ ID 1” as described in Example 1, or a polypeptide having substantial (>85%, >86%, >87%, >88%, >89%, >90%, >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%, >99%) amino-acid sequence identity to the SEQ ID 1 polypeptide as well as isolated nucleic acid molecules that code for those polypeptides.

As used hereinafter, the term “UGTS12”, unless specified otherwise, refers to UDP-glucosyltransferase having amino-acid sequence “SEQ ID 2” as described in Example 1 or a polypeptide having substantial (>85%, >86%, >87%, >88%, >89%, >90%, >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%, >99%) amino-acid sequence identity to the SEQ ID 2 polypeptide as well as isolated nucleic acid molecules that code for those polypeptides.

As used hereinafter, the term “UGT76G1”, unless specified otherwise, refers to UDP-glucosyltransferase having amino-acid sequence “SEQ ID 3” as described in Example 1 or a polypeptide having substantial (>85%, >86%, >87%, >88%, >89%, >90%, >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%, >99%) amino-acid sequence identity to the SEQ ID 3 polypeptide as well as isolated nucleic acid molecules that code for those polypeptides.

In one embodiment, steviol biosynthesis enzymes and UDP-glucosyltransferases are produced in a microbial cell. The microbial cell may be, for example, *E. coli*, *Saccharomyces* sp., *Aspergillus* sp., *Pichia* sp., *Bacillus* sp., *Yarrowia* sp. etc. In another embodiment, the UDP-glucosyltransferases are synthesized.

In one embodiment, the UDP-glucosyltransferase is selected from group including UGT74G1, UGT85C2, UGT76G1, UGT91D2, UGTS12, EUGT11 and UGTs having substantial (>85%, >86%, >87%, >88%, >89%, >90%, >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%, >99%) amino-acid sequence identity to these polypeptides as well as isolated nucleic acid molecules that code for these UGTs.

In one embodiment, steviol biosynthesis enzymes, UGTs, and UDP-glucose recycling system are present in one microorganism (microbial cell). The microorganism may be for example, *E. coli*, *Saccharomyces* sp., *Aspergillus* sp., *Pichia* sp., *Bacillus* sp., *Yarrowia* sp.

In one embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviol or any starting steviol glycoside bearing an -OH functional group at C13 to give a target steviol glycoside having an -O-glucose beta glucopyranoside glycosidic linkage at C13. In a particular embodiment, the UDP-glucosyltransferase is UGT85C2, or a UGT having >85% amino-acid sequence identity with UGT85C2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviol or any starting steviol glycoside bearing a -COOH functional group at C19 to give a target steviol glycoside having a -COO-glucose beta-glucopyranoside glycosidic linkage at C19. In a particular embodiment, the UDP-glucosyltransferase is UGT74G1, or a UGT having >85% amino-acid sequence identity with UGT74G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to any existing glucose on the C19 side of any starting steviol glycoside to give a target steviol glycoside with at least one additional glucose bearing at least one beta 1→2 glucopyranoside glycosidic linkage(s) at the newly formed glycosidic bond(s). In a particular embodiment, the UDP-glucosyltransferase is UGTS12, or a UGT having >85% amino-acid sequence identity with UGTS12. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to any existing glucose on the C19 side of any starting steviol glycoside to give a target steviol glycoside with at least one additional glucose bearing at least one beta 1→3 glucopyranoside glycosidic linkage(s) at the newly formed bond glycosidic bond(s). In a particular embodiment, the UDP-glucosyltransferase is UGT76G1, or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to any existing glucose on

the C19 side of any starting steviol glycoside to give a target steviol glycoside with at least one additional glucose bearing at least one beta 1→4 glucopyranoside glycosidic linkage(s) at the newly formed glycosidic bond(s). In a particular embodiment, the UDP-glucosyltransferase is UGTSl2, or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In another particular embodiment, the UDP-glucosyltransferase is UGT76G1, or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to any existing glucose on the C19 side of any starting steviol glycoside to give a target steviol glycoside with at least one additional glucose bearing at least one beta 1→6 glucopyranoside glycosidic linkage(s) at the newly formed glycosidic bond(s). In a particular embodiment, the UDP-glucosyltransferase is UGTSl2, or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to any existing glucose on the C13 side of any starting steviol glycoside to give a target steviol glycoside with at least one additional glucose bearing at least one beta 1→2 glucopyranoside glycosidic linkage(s) at the newly formed glycosidic bond(s). In a particular embodiment, the UDP-glucosyltransferase is UGTSl2, or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to any existing glucose on

the C13 side of any starting steviol glycoside to give a target steviol glycoside with at least one additional glucose bearing at least one beta 1→3 glucopyranoside glycosidic linkage(s) at the newly formed bond glycosidic bond(s). In a particular embodiment, the UDP-glucosyltransferase is UGT76G1, or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to any existing glucose on the C13 side of any starting steviol glycoside to give a target steviol glycoside with at least one additional glucose bearing at least one beta 1→4 glucopyranoside glycosidic linkage(s) at the newly formed glycosidic bond(s). In a particular embodiment, the UDP-glucosyltransferase is UGT5I2, or a UGT having >85% amino-acid sequence identity with UGT5I2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In another particular embodiment, the UDP-glucosyltransferase is UGT76G1, or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to any existing glucose on the C13 side of any starting steviol glycoside to give a target steviol glycoside with at least one additional glucose bearing at least one beta 1→6 glucopyranoside glycosidic linkage(s) at the newly formed glycosidic bond(s). In a particular embodiment, the UDP-glucosyltransferase is UGT5I2, or a UGT having >85% amino-acid sequence identity with UGT5I2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In one embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviol to form steviolmonoside. In a particular embodiment, the UDP-glucosyltransferase is UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviol to form steviolmonoside *A*. In a particular embodiment, the UDP-glucosyltransferase is UGT74G1 or a UGT having >85% amino-acid sequence identity with UGT74G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolmonoside to form steviolbioside. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolmonoside to form steviolbioside *D*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolmonoside to form rubusoside. In a particular embodiment, the UDP-glucosyltransferase is UGT74G1 or a UGT having >85% amino-acid sequence identity with UGT74G1.

In one embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolmonoside *A* to form rubusoside. In a particular embodiment, the UDP-glucosyltransferase is UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolmonoside *A* to form steviolbioside *A*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-

glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolmonoside *A* to form steviolbioside *B*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside to form rebaudioside *B*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside to form stevioside. In a particular embodiment, the UDP-glucosyltransferase is UGT74G1 or a UGT having >85% amino-acid sequence identity with UGT74G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside *D* to form rebaudioside *B*. In a particular embodiment, the UDP-glucosyltransferase is UGTS12 or a UGT having >85% amino-acid sequence identity with UGTS12. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside *D* to form rebaudioside *G*. In a particular embodiment, the UDP-glucosyltransferase is UGT74G1 or a UGT having >85% amino-acid sequence identity with UGT74G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rubusoside to form stevioside. In a particular embodiment, the UDP-glucosyltransferase is UGTS12 or a UGT having >85% amino-acid sequence identity with UGTS12. In another particular

embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rubusoside to form rebaudioside *G*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rubusoside to form stevioside *A*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rubusoside to form stevioside *B*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In one embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside *A* to form stevioside *A*. In a particular embodiment, the UDP-glucosyltransferase is UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside *A* to form stevioside *C*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In one embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside *B* to form stevioside *B*. In a particular embodiment, the UDP-glucosyltransferase is UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside *B* to form stevioside *C*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *B* to form rebaudioside *A*. In a particular embodiment, the UDP-glucosyltransferase is UGT74G1 or a UGT having >85% amino-acid sequence identity with UGT74G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside to form rebaudioside *A*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside to form rebaudioside *E*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside to form

rebaudioside *E2*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *G* to form rebaudioside *A*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *G* to form rebaudioside *E4*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *G* to form rebaudioside *E6*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside *A* to form rebaudioside *E*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside *A* to form rebaudioside *E4*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside *A* to form rebaudioside *E3*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside *B* to form rebaudioside *E2*. In a particular embodiment, the UDP-glucosyltransferase is UGTS12 or a UGT having >85% amino-acid sequence identity with UGTS12. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside *B* to form rebaudioside *E6*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside *B* to form rebaudioside *E3*. In a particular embodiment, the UDP-glucosyltransferase is UGTS12 or a UGT having >85% amino-acid sequence identity with UGTS12. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In one embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside *C* to form rebaudioside *E3*. In a particular embodiment, the UDP-glucosyltransferase is UGT85C2 or a UGT having >85%

amino-acid sequence identity with UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *A* to form rebaudioside *D*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *A* to form rebaudioside *I*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E* to form rebaudioside *D*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E* to form rebaudioside *AM*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E2* to form rebaudioside *I*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E2* to form rebaudioside *AM*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular

embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E4* to form rebaudioside *D*. In a particular embodiment, the UDP-glucosyltransferase is UGTS12 or a UGT having >85% amino-acid sequence identity with UGTS12. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E4* to form rebaudioside *D7*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E6* to form rebaudioside *I*. In a particular embodiment, the UDP-glucosyltransferase is UGTS12 or a UGT having >85% amino-acid sequence identity with UGTS12. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E6* to form rebaudioside *D7*. In a particular embodiment, the UDP-glucosyltransferase is UGTS12 or a UGT having >85% amino-acid sequence identity with UGTS12. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-

glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E3* to form rebaudioside *AM*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E3* to form rebaudioside *D7*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *D* to form rebaudioside *M*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *I* to form rebaudioside *M*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *AM* to form rebaudioside *M*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *AM* to form rebaudioside *M4*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *AM* to form rebaudioside *M5*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *D7* to form rebaudioside *M*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *1a*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-

glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *1b*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *1c*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *1d*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *1e*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *1f*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid

sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Ig*. In a particular embodiment, the UDP-glucosyltransferase is UGTSI2 or a UGT having >85% amino-acid sequence identity with UGTSI2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Ih*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Ii*. In a particular embodiment, the UDP-glucosyltransferase is UGTSI2 or a UGT having >85% amino-acid sequence identity with UGTSI2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Ij*. In a particular embodiment, the UDP-glucosyltransferase is UGTSI2 or a UGT having >85% amino-acid sequence identity with UGTSI2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Ik*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Il*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Im*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *In*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Io*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a

UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *lp*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *lq*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *lr*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity

with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Is*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *It*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2a*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form

rebaudioside 2*b*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside 2*c*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside 2*d*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside 2*e*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside 2*f*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside 2g. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside 2h. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside 2i. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside 2j. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form

rebaudioside *2k*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2l*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2m*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2n*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2o*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid

sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2p*. In a particular embodiment, the UDP-glucosyltransferase is UGTSI2 or a UGT having >85% amino-acid sequence identity with UGTSI2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2q*. In a particular embodiment, the UDP-glucosyltransferase is UGTSI2 or a UGT having >85% amino-acid sequence identity with UGTSI2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2r*. In a particular embodiment, the UDP-glucosyltransferase is UGTSI2 or a UGT having >85% amino-acid sequence identity with UGTSI2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2s*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *1q*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M5* to form rebaudioside *1m*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M5* to form rebaudioside *2m*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid

sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

Optionally, the method of the present invention further comprises recycling UDP to provide UDP-glucose. In one embodiment, the method comprises recycling UDP by providing a recycling catalyst and a recycling substrate, such that the biotransformation of steviol and/or the steviol glycoside substrate to the target steviol glycoside is carried out using catalytic amounts of UDP-glucosyltransferase and UDP-glucose.

In one embodiment, the recycling catalyst is sucrose synthase SuSy_At or a sucrose synthase having >85% amino-acid sequence identity with SuSy_At.

In one embodiment, the recycling substrate for UDP-glucose recycling catalyst is sucrose.

Optionally, the method of the present invention further comprises the use of transglycosidases that use oligo- or poly-saccharides as the sugar donor to modify recipient target steviol glycoside molecules. Non-limiting examples include cyclodextrin glycosyltransferase (CGTase), fructofuranosidase, amylase, saccharase, glucosucrase, beta-h-fructosidase, beta-fructosidase, sucrase, fructosylinvertase, alkaline invertase, acid invertase, fructofuranosidase. In some embodiments, glucose and sugar(s) other than glucose, including but not limited to fructose, xylose, rhamnose, arabinose, deoxyglucose, galactose are transferred to the recipient target steviol glycosides. In one embodiment, the recipient steviol glycoside is rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, and/or rebaudioside *2s*. In another embodiment, the recipient steviol glycoside is rebaudioside *M4*.

In another embodiment, the recipient steviol glycoside is rebaudioside *M5*. In another embodiment, the recipient steviol glycoside is SvG7.

Optionally, the method of the present invention further comprises separating the target steviol glycoside from the medium to provide a highly purified target steviol glycoside composition. The target steviol glycoside can be separated by at least one suitable method, such as, for example, crystallization, separation by membranes, centrifugation, extraction, chromatographic separation or a combination of such methods.

In one embodiment, the target steviol glycoside can be produced within the microorganism. In another embodiment, the target steviol glycoside can be secreted out in the medium. In one another embodiment, the released steviol glycoside can be continuously removed from the medium. In yet another embodiment, the target steviol glycoside is separated after the completion of the conversion reaction.

In one embodiment, separation produces a composition comprising greater than about 80% by weight of the target steviol glycoside on an anhydrous basis, i.e., a highly purified steviol glycoside composition. In another embodiment, separation produces a composition comprising greater than about 90% by weight of the target steviol glycoside. In particular embodiments, the composition comprises greater than about 95% by weight of the target steviol glycoside. In other embodiments, the composition comprises greater than about 99% by weight of the target steviol glycoside.

The target steviol glycoside can be in any polymorphic or amorphous form, including hydrates, solvates, anhydrous or combinations thereof.

Purified target steviol glycosides can be used in consumable products as a sweetener, flavor modifier, flavor with modifying properties and/or foaming suppressor. Suitable consumer products include, but are not limited to, food, beverages, pharmaceutical compositions, tobacco products, nutraceutical compositions, oral hygiene compositions, and cosmetic compositions.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1a through FIG. 1t show the chemical structure of some SvG7 steviol glycosides rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*,

rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s* and rebaudioside *1t* respectively.

FIG. 2a through FIG. 2s show the chemical structure of some SvG7 steviol glycosides rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r* and rebaudioside *2s* respectively.

FIG. 3a through FIG. 3b show the chemical structure of rebaudioside *M4* and rebaudioside *M5* respectively.

FIG. 4a through FIG. 4t show the pathways of producing rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s* and rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, and rebaudioside *2s*, rebaudioside *M4*, rebaudioside *M5* and various steviol glycosides from steviol and the various intermediary steviol glycosides.

FIG. 5a through FIG. 5t show the biocatalytic production of rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m* and rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s* and rebaudioside *1t* respectively, from rebaudioside *A* using the enzymes UGT512 and UGT76G1 and concomitant recycling of UDP to UDP-glucose via sucrose synthase SuSy_{At}.

FIG. 6a through FIG. 6t show the biocatalytic production of rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*,

rebaudioside *2r*, rebaudioside *2s* and rebaudioside *1q*, respectively, from stevioside using the enzymes UGTSl2 and UGT76G1 and concomitant recycling of UDP to UDP-glucose via sucrose synthase SuSy_At.

FIG. 7a through FIG. 7b show the biocatalytic production of rebaudioside *M4* and rebaudioside *M5*, respectively from stevioside using the enzymes UGTSl2 and UGT76G1 and concomitant recycling of UDP to UDP-glucose via sucrose synthase SuSy_At.

FIG. 8a through FIG. 8t show the biocatalytic production of rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and rebaudioside *1q*, respectively, from rebaudioside *AM* using the enzymes UGTSl2 and UGT76G1 and concomitant recycling of UDP to UDP-glucose via sucrose synthase SuSy_At.

FIG. 9a through 9b show the biocatalytic production of rebaudioside *M4* and rebaudioside *M5*, respectively from rebaudioside *AM* using the enzymes UGTSl2 and UGT76G1 and concomitant recycling of UDP to UDP-glucose via sucrose synthase SuSy_At.

FIG. 10a through FIG. 10t show the biocatalytic production of rebaudioside *2a* rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and rebaudioside *1q*, respectively, from rebaudioside *M4* using the enzymes UGTSl2 and UGT76G1 and concomitant recycling of UDP to UDP-glucose via sucrose synthase SuSy_At.

FIG. 11a through FIG. 11b show the biocatalytic production of rebaudioside *1m* and rebaudioside *2m*, respectively, from rebaudioside *M5* using the enzymes UGTSl2 and UGT76G1 and concomitant recycling of UDP to UDP-glucose via sucrose synthase SuSy_At.

FIG. 12a shows the HPLC chromatogram of stevioside. The peak with retention time of 20.958 minutes corresponds to stevioside. The peak with retention time 20.725 minutes corresponds to rebaudioside *A*. The peak at 32.925 minutes corresponds to rebaudioside *B*. The peak at 33.930 minutes corresponds to steviolbioside.

FIG. 12b shows the HPLC chromatogram of the product of the biocatalytic production of SvG7 molecules from stevioside. The peak at 5.089 minutes corresponds to rebaudioside *2m*. The peak at 5.350 minutes corresponds to rebaudioside *M5*. The peak at 6.459 minutes corresponds to rebaudioside *2a*. The peak at 9.825 minutes corresponds to rebaudioside *AM*. The peak at 13.845 minutes corresponds to rebaudioside *M*. The peak at 32.974 minutes corresponds to rebaudioside *B*. The peak at 33.979 minutes corresponds to steviolbioside.

FIG. 12c shows the HPLC chromatogram of rebaudioside *2a* after purification by HPLC. The peak with retention time of 6.261 minutes correspond to rebaudioside *2a*.

FIG. 12d shows the HPLC chromatogram of rebaudioside *2m* after purification by HPLC. The peak with retention time of 5.197 minutes correspond to rebaudioside *2m*.

FIG. 12e shows the HPLC chromatogram of rebaudioside *M5* after purification by HPLC. The peak with retention time of 5.242 minutes correspond to rebaudioside *M5*.

FIG. 13a shows the ¹H NMR spectrum of rebaudioside *2a* (500 MHz, pyridine-*d*₅).

FIG. 13b shows the HSQC spectrum of rebaudioside *2a* (500 MHz, pyridine-*d*₅).

FIG. 13c shows the H,H COSY spectrum of rebaudioside *2a* (500 MHz, pyridine-*d*₅).

FIG. 13d shows the HMBC spectrum of rebaudioside *2a* (500 MHz, pyridine-*d*₅).

FIG. 13e shows the HSQC-TOCSY spectrum of rebaudioside *2a* (500 MHz, pyridine-*d*₅).

FIG. 13f shows the 1D-NOESY spectrum of rebaudioside *2a* (500 MHz, pyridine-*d*₅).

FIG. 13g shows the LC chromatogram of rebaudioside *2a*.

FIG. 13h shows the mass spectrum of rebaudioside *2a*.

FIG. 14a shows the ¹H NMR spectrum of rebaudioside *2m* (500 MHz, pyridine-*d*₅).

FIG. 14b shows the HSQC spectrum of rebaudioside *2m* (500 MHz, pyridine-*d*5).

FIG. 14c shows the H,H COSY spectrum of rebaudioside *2m* (500 MHz, pyridine-*d*5).

FIG. 14d shows the HMBC spectrum of rebaudioside *2m* (500 MHz, pyridine-*d*5).

FIG. 14e shows the HSQC-TOCSY spectrum of rebaudioside *2m* (500 MHz, pyridine-*d*5).

FIG. 14f shows the 1D-NOESY spectrum of rebaudioside *2m* (500 MHz, pyridine-*d*5).

FIG. 14g shows the LC chromatogram of rebaudioside *2m*.

FIG. 14h shows the mass spectrum of rebaudioside *2m*.

FIG. 15a shows the ¹H NMR spectrum of rebaudioside *M5* (500 MHz, pyridine-*d*5).

FIG. 15b shows the HSQC spectrum of rebaudioside *M5* (500 MHz, pyridine-*d*5).

FIG. 15c shows the H,H COSY spectrum of rebaudioside *M5* (500 MHz, pyridine-*d*5).

FIG. 15d shows the HMBC spectrum of rebaudioside *M5* (500 MHz, pyridine-*d*5).

FIG. 15e shows the HSQC-TOCSY spectrum of rebaudioside *M5* (500 MHz, pyridine-*d*5).

FIG. 15f shows the 1D-NOESY spectrum of rebaudioside *M5* (500 MHz, pyridine-*d*5).

FIG. 15g shows the LC chromatogram of rebaudioside *M5*.

FIG. 15h shows the mass spectrum of rebaudioside *M5*.

DETAILED DESCRIPTION

The present invention provides a process for preparing a composition comprising a target steviol glycoside by contacting a starting composition comprising an organic substrate with a microbial cell and/or enzyme preparation, thereby producing a composition comprising a target steviol glycoside.

One object of the invention is to provide an efficient biocatalytic method for preparing target steviol glycosides, particularly steviolmonoside, steviolmonoside *A*,

steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s*, and/or SvG7 or a synthetic steviol glycoside from various starting compositions.

Starting Composition

As used herein, “starting composition” refers to any composition (generally an aqueous solution) containing one or more organic compound comprising at least one carbon atom.

In one embodiment, the starting composition is selected from the group consisting of steviol, steviol glycosides, polyols and various carbohydrates.

The starting composition steviol glycoside is selected from the group consisting of steviol, steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4* and/or rebaudioside *M5* or other glycoside of steviol occurring in *Stevia rebaudiana* plant, synthetic steviol glycosides, e.g. enzymatically glucosylated steviol glycosides and combinations thereof.

In one embodiment, the starting composition is steviol.

In another embodiment, the starting composition steviol glycoside is steviolmonoside.

In yet another embodiment, the starting composition steviol glycoside is steviolmonoside *A*.

In another embodiment, the starting composition steviol glycoside is steviolbioside.

In another embodiment, the starting composition steviol glycoside is steviolbioside *D*.

In another embodiment, the starting composition steviol glycoside is rubusoside.

In another embodiment, the starting composition steviol glycoside is steviolbioside *A*.

In another embodiment, the starting composition steviol glycoside is steviolbioside *B*.

In another embodiment, the starting composition steviol glycoside is rebaudioside *B*.

In another embodiment, the starting composition steviol glycoside is stevioside.

In another embodiment, the starting composition steviol glycoside is rebaudioside *G*.

In another embodiment, the starting composition steviol glycoside is stevioside *A*.

In another embodiment, the starting composition steviol glycoside is stevioside *B*.

In another embodiment, the starting composition steviol glycoside is stevioside *C*.

In another embodiment, the starting composition steviol glycoside is rebaudioside *A*.

In another embodiment, the starting composition steviol glycoside is rebaudioside *E*.

In another embodiment, the starting composition steviol glycoside is rebaudioside *E2*.

In another embodiment, the starting composition steviol glycoside is rebaudioside *E4*.

In another embodiment, the starting composition steviol glycoside is rebaudioside *E6*.

In another embodiment, the starting composition steviol glycoside is rebaudioside *E3*.

In another embodiment, the starting composition steviol glycoside is rebaudioside *D*.

In another embodiment, the starting composition steviol glycoside is rebaudioside *I*.

In another embodiment, the starting composition steviol glycoside is rebaudioside *AM*.

In another embodiment, the starting composition steviol glycoside is rebaudioside *D7*.

In another embodiment, the starting composition steviol glycoside is rebaudioside *M*.

In another embodiment, the starting composition steviol glycoside is rebaudioside *M4*.

In another embodiment, the starting composition steviol glycoside is rebaudioside *M5*.

The term “polyol” refers to a molecule that contains more than one hydroxyl group. A polyol may be a diol, triol, or a tetraol which contain 2, 3, and 4 hydroxyl groups, respectively. A polyol also may contain more than four hydroxyl groups, such as a pentaol, hexaol, heptaol, or the like, which contain 5, 6, or 7 hydroxyl groups, respectively. Additionally, a polyol also may be a sugar alcohol, polyhydric alcohol, or polyalcohol which is a reduced form of carbohydrate, wherein the carbonyl group (aldehyde or ketone, reducing sugar) has been reduced to a primary or secondary hydroxyl group. Examples of polyols include, but are not limited to, erythritol, maltitol, mannitol, sorbitol, lactitol, xylitol, inositol, isomalt, propylene glycol, glycerol, threitol, galactitol, hydrogenated isomaltulose, reduced isomalto-oligosaccharides, reduced xylo-oligosaccharides, reduced gentio-oligosaccharides, reduced maltose syrup, reduced glucose syrup, hydrogenated starch hydrolyzates, polyglycitols and sugar alcohols or any other carbohydrates capable of being reduced.

The term “carbohydrate” refers to aldehyde or ketone compounds substituted with multiple hydroxyl groups, of the general formula $(CH_2O)_n$, wherein n is 3-30, as well as their oligomers and polymers. The carbohydrates of the present invention can, in addition, be substituted or deoxygenated at one or more positions. Carbohydrates, as used herein, encompass unmodified carbohydrates, carbohydrate derivatives, substituted carbohydrates, and modified carbohydrates. As used herein, the phrases “carbohydrate derivatives”, “substituted carbohydrate”, and “modified carbohydrates” are synonymous. Modified carbohydrate means any carbohydrate wherein at least one atom has been added, removed, or substituted, or combinations thereof. Thus, carbohydrate derivatives or substituted carbohydrates include substituted and unsubstituted monosaccharides, disaccharides, oligosaccharides, and polysaccharides. The carbohydrate derivatives or substituted carbohydrates optionally can be deoxygenated at any corresponding C-position, and/or substituted with one or more moieties such as hydrogen, halogen, haloalkyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy,

aryloxy, nitro, cyano, sulfo, mercapto, imino, sulfonyl, sulfenyl, sulfinyl, sulfamoyl, carboalkoxy, carboxamido, phosphonyl, phosphinyl, phosphoryl, phosphino, thioester, thioether, oximino, hydrazino, carbamyl, phospho, phosphonato, or any other viable functional group provided the carbohydrate derivative or substituted carbohydrate functions to improve the sweet taste of the sweetener composition.

Examples of carbohydrates which may be used in accordance with this invention include, but are not limited to, tagatose, trehalose, galactose, rhamnose, various cyclodextrins, cyclic oligosaccharides, various types of maltodextrins, dextran, sucrose, glucose, ribulose, fructose, threose, arabinose, xylose, lyxose, allose, altrose, mannose, idose, lactose, maltose, invert sugar, isotrehalose, neotrehalose, isomaltulose, erythrose, deoxyribose, gulose, idose, talose, erythrulose, xylulose, psicose, turanose, cellobiose, amylopectin, glucosamine, mannosamine, fucose, glucuronic acid, gluconic acid, gluconolactone, abequose, galactosamine, beet oligosaccharides, isomalto-oligosaccharides (isomaltose, isomaltotriose, panose and the like), xylo-oligosaccharides (xylotriose, xylobiose and the like), xylo-terminated oligosaccharides, gentio-oligosaccharides (gentiobiose, gentiotriose, gentiotetraose and the like), sorbose, nigero-oligosaccharides, palatinose oligosaccharides, fructooligosaccharides (kestose, nystose and the like), maltotetraol, maltotriol, malto-oligosaccharides (maltotriose, maltotetraose, maltopentaose, maltohexaose, maltoheptaose and the like), starch, inulin, inulo-oligosaccharides, lactulose, melibiose, raffinose, ribose, isomerized liquid sugars such as high fructose corn syrups, coupling sugars, and soybean oligosaccharides. Additionally, the carbohydrates as used herein may be in either the D- or L-configuration.

The starting composition may be synthetic or purified (partially or entirely), commercially available or prepared.

In one embodiment, the starting composition is glycerol.

In another embodiment, the starting composition is glucose.

In another embodiment, the starting composition is rhamnose.

In still another embodiment, the starting composition is sucrose.

In yet another embodiment, the starting composition is starch.

In another embodiment, the starting composition is maltodextrin.

In yet another embodiment, the starting composition is cellulose.

In still another embodiment, the starting composition is amylose.

The organic compound(s) of starting composition serve as a substrate(s) for the production of the target steviol glycoside(s), as described herein.

Target Steviol Glycoside

The target steviol glycoside of the present method can be any steviol glycoside that can be prepared by the process disclosed herein. In one embodiment, the target steviol glycoside is selected from the group consisting of steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s*, SvG7 or other glycoside of steviol occurring in *Stevia rebaudiana* plant, synthetic steviol glycosides, e.g. enzymatically glucosylated steviol glycosides and combinations thereof.

In one embodiment, the target steviol glycoside is steviolmonoside.

In another embodiment, the target steviol glycoside is steviolmonoside *A*.

In another embodiment, the target steviol glycoside is steviolbioside.

In another embodiment, the target steviol glycoside is steviolbioside *D*.

In another embodiment, the target steviol glycoside is rubusoside.

In another embodiment, the target steviol glycoside is steviolbioside *A*.

In another embodiment, the target steviol glycoside is steviolbioside *B*.

In another embodiment, the target steviol glycoside is rebaudioside *B*.

In another embodiment, the target steviol glycoside is stevioside.

In another embodiment, the target steviol glycoside is rebaudioside *G*.

In another embodiment, the target steviol glycoside is stevioside *A*.

In another embodiment, the target steviol glycoside is stevioside *B*.

In another embodiment, the target steviol glycoside is stevioside *C*.

In another embodiment, the target steviol glycoside is rebaudioside *A*.

In another embodiment, the target steviol glycoside is rebaudioside *E*.

In another embodiment, the target steviol glycoside is rebaudioside *E2*.

In another embodiment, the target steviol glycoside is rebaudioside *E4*.

In another embodiment, the target steviol glycoside is rebaudioside *E6*.

In another embodiment, the target steviol glycoside is rebaudioside *E3*.

In another embodiment, the target steviol glycoside is rebaudioside *D*.

In another embodiment, the target steviol glycoside is rebaudioside *I*.

In another embodiment, the target steviol glycoside is rebaudioside *AM*.

In another embodiment, the target steviol glycoside is rebaudioside *D7*.

In another embodiment, the target steviol glycoside is rebaudioside *M*.

In another embodiment, the target steviol glycoside is rebaudioside *M4*.

In another embodiment, the target steviol glycoside is rebaudioside *M5*.

In another embodiment, the target steviol glycoside is rebaudioside *1a*.

In another embodiment, the target steviol glycoside is rebaudioside *1b*.

In another embodiment, the target steviol glycoside is rebaudioside *1c*.

In another embodiment, the target steviol glycoside is rebaudioside *1d*.

In another embodiment, the target steviol glycoside is rebaudioside *1e*.

In another embodiment, the target steviol glycoside is rebaudioside *1f*.

In another embodiment, the target steviol glycoside is rebaudioside *1g*.

In another embodiment, the target steviol glycoside is rebaudioside *1h*.

In another embodiment, the target steviol glycoside is rebaudioside *1i*.

In another embodiment, the target steviol glycoside is rebaudioside *1j*.

In another embodiment, the target steviol glycoside is rebaudioside *1k*.

In another embodiment, the target steviol glycoside is rebaudioside *1l*.

In another embodiment, the target steviol glycoside is rebaudioside *1m*.

In another embodiment, the target steviol glycoside is rebaudioside *1n*.

In another embodiment, the target steviol glycoside is rebaudioside *1o*.

In another embodiment, the target steviol glycoside is rebaudioside *1p*.

In another embodiment, the target steviol glycoside is rebaudioside *1q*.

In another embodiment, the target steviol glycoside is rebaudioside *1r*.

In another embodiment, the target steviol glycoside is rebaudioside *1s*.

In another embodiment, the target steviol glycoside is rebaudioside *1t*.

In another embodiment, the target steviol glycoside is rebaudioside *2a*.

In another embodiment, the target steviol glycoside is rebaudioside *2b*.

In another embodiment, the target steviol glycoside is rebaudioside *2c*.

In another embodiment, the target steviol glycoside is rebaudioside *2d*.

In another embodiment, the target steviol glycoside is rebaudioside *2e*.

In another embodiment, the target steviol glycoside is rebaudioside *2f*.

In another embodiment, the target steviol glycoside is rebaudioside *2g*.

In another embodiment, the target steviol glycoside is rebaudioside *2h*.

In another embodiment, the target steviol glycoside is rebaudioside *2i*.

In another embodiment, the target steviol glycoside is rebaudioside *2j*.

In another embodiment, the target steviol glycoside is rebaudioside *2k*.

In another embodiment, the target steviol glycoside is rebaudioside *2l*.

In another embodiment, the target steviol glycoside is rebaudioside *2m*.

In another embodiment, the target steviol glycoside is rebaudioside *2n*.

In another embodiment, the target steviol glycoside is rebaudioside *2o*.

In another embodiment, the target steviol glycoside is rebaudioside *2p*.

In another embodiment, the target steviol glycoside is rebaudioside *2q*.

In another embodiment, the target steviol glycoside is rebaudioside *2r*.

In another embodiment, the target steviol glycoside is rebaudioside *2s*.

In another embodiment, the target steviol glycoside is SvG7.

The target steviol glycoside can be in any polymorphic or amorphous form, including hydrates, solvates, anhydrous or combinations thereof.

In one embodiment, the present invention is a biocatalytic process for the production of steviolmonoside.

In one embodiment, the present invention is a biocatalytic process for the production of steviolmonoside *A*.

In one embodiment, the present invention is a biocatalytic process for the production of steviolbioside.

In one embodiment, the present invention is a biocatalytic process for the production of steviolbioside *D*.

In one embodiment, the present invention is a biocatalytic process for the production of rubusoside.

In one embodiment, the present invention is a biocatalytic process for the production of steviolbioside *A*.

In one embodiment, the present invention is a biocatalytic process for the production of steviolbioside *B*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *B*.

In one embodiment, the present invention is a biocatalytic process for the production of stevioside.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *G*.

In one embodiment, the present invention is a biocatalytic process for the production of stevioside *A*.

In one embodiment, the present invention is a biocatalytic process for the production of stevioside *B*.

In one embodiment, the present invention is a biocatalytic process for the production of stevioside *C*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *A*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *E*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *E2*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *E4*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *E6*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *E3*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *D*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *I*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *AM*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *D7*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *E3*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *M*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *M4*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *M5*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *1a*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *1b*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *1c*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *1d*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *1e*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *1f*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *1g*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *1h*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *1i*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *1j*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *1k*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *1l*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *Im*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *In*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *Io*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *Ip*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *Iq*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *Ir*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *Is*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *It*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2a*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2b*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2c*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2d*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2e*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2f*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2g*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2h*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2i*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2j*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2k*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2l*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2m*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2n*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2o*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2p*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2q*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside *2r*.

In one embodiment, the present invention is a biocatalytic process for the production of rebaudioside 2s.

In one embodiment, the present invention is a biocatalytic process for the production of SvG7.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1a* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1b* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1c* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1d* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1e* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1f* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1g* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1h* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *li* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *lj* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *lk* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *ll* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *lm* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *ln* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *lo* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *lp* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *lq* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1r* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1s* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1t* from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2a* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2b* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2c* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2d* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2e* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2f* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2g* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2h* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2i* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2j* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2k* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2l* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2m* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2n* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2o* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2p* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2q* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2r* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2s* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1q* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *M4* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *M5* from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2a* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2b* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2c* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2d* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2e* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2f* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2g* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2h* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2i* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2j* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2k* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2l* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2m* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2n* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2o* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2p* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2q* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2r* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2s* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1q* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *M4* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *M5* from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2a* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2b* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2c* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2d* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2e* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2f* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2g* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2h* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2i* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2j* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2k* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2l* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2m* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2n* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2o* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2p* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2q* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2r* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2s* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1q* from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1m* from a starting composition comprising rebaudioside *M5* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *2m* from a starting composition comprising rebaudioside *M5* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1a* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1b* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *1c* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *Id* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *Ie* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *If* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *Ig* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *Ih* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *Ii* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *Ij* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *Ik* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *Il* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *Im* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *In* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *Io* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *Ip* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *Iq* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *Ir* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *Is* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of rebaudioside *It* from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of SvG7 from a starting composition comprising stevioside and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of SvG7 from a starting composition comprising rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of SvG7 from a starting composition comprising stevioside, rebaudioside *A* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of SvG7 from a starting composition comprising rebaudioside *AM* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of SvG7 from a starting composition comprising rebaudioside *M* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of SvG7 from a starting composition comprising rebaudioside *M4* and UDP-glucose.

In a particular embodiment, the present invention provides for the biocatalytic process for the production of SvG7 from a starting composition comprising rebaudioside *M5* and UDP-glucose.

Optionally, the method of the present invention further comprises separating the target steviol glycoside from the medium to provide a highly purified target steviol glycoside composition. The target steviol glycoside can be separated by any suitable method, such as, for example, crystallization, separation by membranes, centrifugation, extraction, chromatographic separation or a combination of such methods.

In particular embodiments, the process described herein results in a highly purified target steviol glycoside composition. The term “highly purified”, as used herein, refers to a composition having greater than about 80% by weight of the target steviol glycoside on an anhydrous (dried) basis. In one embodiment, the highly purified target steviol glycoside composition contains greater than about 90% by weight of the target steviol glycoside on an anhydrous (dried) basis, such as, for example, greater than about 91%, greater than about

92%, greater than about 93%, greater than about 94%, greater than about 95%, greater than about 96%, greater than about 97%, greater than about 98% or greater than about 99% target steviol glycoside content on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *M4*, the process described herein provides a composition having greater than about 90% rebaudioside *M4* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *M4*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *M5*, the process described herein provides a composition having greater than about 90% rebaudioside *M5* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *M5*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *1a*, the process described herein provides a composition having greater than about 90% rebaudioside *1a* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *1a*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *1b*, the process described herein provides a composition having greater than about 90% rebaudioside *1b* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *1b*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *1c*, the process described herein provides a composition having greater than about 90% rebaudioside *1c* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *1c*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *1d*, the process described herein provides a composition having greater than about 90% rebaudioside *1d*

content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *Id*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *Ie*, the process described herein provides a composition having greater than about 90% rebaudioside *Ie* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *Ie*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *If*, the process described herein provides a composition having greater than about 90% rebaudioside *If* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *If*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *Ig*, the process described herein provides a composition having greater than about 90% rebaudioside *Ig* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *Ig*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *Ih*, the process described herein provides a composition having greater than about 90% rebaudioside *Ih* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *Ih*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *Ii*, the process described herein provides a composition having greater than about 90% rebaudioside *Ii* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *Ii*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *Ij*, the process described herein provides a composition having greater than about 90% rebaudioside *Ij*

content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *1j*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *1k*, the process described herein provides a composition having greater than about 90% rebaudioside *1k* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *1k*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *1l*, the process described herein provides a composition having greater than about 90% rebaudioside *1l* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *1l*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *1m*, the process described herein provides a composition having greater than about 90% rebaudioside *1m* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *1m*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *1n*, the process described herein provides a composition having greater than about 90% rebaudioside *1n* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *1n*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *1o*, the process described herein provides a composition having greater than about 90% rebaudioside *1o* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *1o*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *1p*, the process described herein provides a composition having greater than about 90% rebaudioside *1p*

content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *1p*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *1q*, the process described herein provides a composition having greater than about 90% rebaudioside *1q* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *1q*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *1r*, the process described herein provides a composition having greater than about 90% rebaudioside *1r* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *1r*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *1s*, the process described herein provides a composition having greater than about 90% rebaudioside *1s* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *1s*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *1t*, the process described herein provides a composition having greater than about 90% rebaudioside *1t* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *1t*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2a*, the process described herein provides a composition having greater than about 90% rebaudioside *2a* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2a*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2b*, the process described herein provides a composition having greater than about 90% rebaudioside *2b*

content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2b*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2c*, the process described herein provides a composition having greater than about 90% rebaudioside *2c* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2c*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2d*, the process described herein provides a composition having greater than about 90% rebaudioside *2d* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2d*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2e*, the process described herein provides a composition having greater than about 90% rebaudioside *2e* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2e*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2f*, the process described herein provides a composition having greater than about 90% rebaudioside *2f* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2f*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2g*, the process described herein provides a composition having greater than about 90% rebaudioside *2g* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2g*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2h*, the process described herein provides a composition having greater than about 90% rebaudioside *2h*

content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2h*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2i*, the process described herein provides a composition having greater than about 90% rebaudioside *2i* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2i*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2j*, the process described herein provides a composition having greater than about 90% rebaudioside *2j* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2j*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2k*, the process described herein provides a composition having greater than about 90% rebaudioside *2k* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2k*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2l*, the process described herein provides a composition having greater than about 90% rebaudioside *2l* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2l*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2m*, the process described herein provides a composition having greater than about 90% rebaudioside *2m* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2m*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2n*, the process described herein provides a composition having greater than about 90% rebaudioside *2n*

content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2n*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2o*, the process described herein provides a composition having greater than about 90% rebaudioside *2o* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2o*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2p*, the process described herein provides a composition having greater than about 90% rebaudioside *2p* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2p*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2q*, the process described herein provides a composition having greater than about 90% rebaudioside *2q* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2q*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2r*, the process described herein provides a composition having greater than about 90% rebaudioside *2r* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2r*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is rebaudioside *2s*, the process described herein provides a composition having greater than about 90% rebaudioside *2s* content by weight on a dried basis. In another particular embodiment, when the target steviol glycoside is rebaudioside *2s*, the process described herein provides a composition comprising greater than about 95% content by weight on a dried basis.

In one embodiment, when the target steviol glycoside is SvG7, the process described herein provides a composition having greater than about 90% SvG7 content by weight on a

dried basis. In another particular embodiment, when the target steviol glycoside is SvG7, the process described herein provides a composition comprising greater than about 95% SvG7 content by weight on a dried basis.

Microorganisms and enzyme preparations

In one embodiment of present invention, a microorganism (microbial cell) and/or enzyme preparation is contacted with a medium containing the starting composition to produce target steviol glycosides.

The enzyme can be provided in the form of a whole cell suspension, a crude lysate, a purified enzyme or a combination thereof. In one embodiment, the biocatalyst is a purified enzyme capable of converting the starting composition to the target steviol glycoside. In another embodiment, the biocatalyst is a crude lysate comprising at least one enzyme capable of converting the starting composition to the target steviol glycoside. In still another embodiment, the biocatalyst is a whole cell suspension comprising at least one enzyme capable of converting the starting composition to the target steviol glycoside.

In another embodiment, the biocatalyst is one or more microbial cells comprising enzyme(s) capable of converting the starting composition to the target steviol glycoside. The enzyme can be located on the surface of the cell, inside the cell or located both on the surface of the cell and inside the cell.

Suitable enzymes for converting the starting composition to target steviol glycosides include, but are not limited to, the steviol biosynthesis enzymes, NDP-glucosyltransferases (NGTs), ADP-glucosyltransferases (AGTs), CDP-glucosyltransferases (CGTs), GDP-glucosyltransferases (GGTs), TDP-glucosyltransferases (TDPs), UDP-glucosyltransferases (UGTs). Optionally it may include NDP-recycling enzyme(s), ADP-recycling enzyme(s), CDP-recycling enzyme(s), GDP-recycling enzyme(s), TDP-recycling enzyme(s), and/or UDP-recycling enzyme(s).

In one embodiment, the steviol biosynthesis enzymes include mevalonate (MVA) pathway enzymes.

In another embodiment, the steviol biosynthesis enzymes include non-mevalonate 2-C-methyl-D-erythritol-4-phosphate pathway (MEP/DOXP) enzymes.

In one embodiment the steviol biosynthesis enzymes are selected from the group including geranylgeranyl diphosphate synthase, copalyl diphosphate synthase, kaurene synthase, kaurene oxidase, kaurenoic acid 13-hydroxylase (KAH), steviol synthetase, deoxyxylulose 5-phosphate synthase (DXS), D-1-deoxyxylulose 5-phosphate reductoisomerase (DXR), 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase (CMS), 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (CMK), 4-diphosphocytidyl-2-C-methyl-D-erythritol 2,4- cyclodiphosphate synthase (MCS), 1-hydroxy-2-methyl-2(E)-butenyl 4-diphosphate synthase (HDS), 1-hydroxy-2-methyl-2(E)-butenyl 4-diphosphate reductase (HDR), acetoacetyl-CoA thiolase, truncated HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, mevalonate pyrophosphate decarboxylase, cytochrome P450 reductase etc.

The UDP-glucosyltransferase can be any UDP-glucosyltransferase capable of adding at least one glucose unit to steviol and/or a steviol glycoside substrate to provide the target steviol glycoside.

In one embodiment, steviol biosynthesis enzymes and UDP-glucosyltransferases are produced in a microbial cell. The microbial cell may be, for example, *E. coli*, *Saccharomyces* sp., *Aspergillus* sp., *Pichia* sp., *Bacillus* sp., *Yarrowia* sp. etc. In another embodiment, the UDP-glucosyltransferases are synthesized.

In one embodiment, the UDP-glucosyltransferase is selected from group including UGT74G1, UGT85C2, UGT76G1, UGT91D2, UGT5I2, EUGT11 and UGTs having substantial (>85%, >86%, >87%, >88%, >89%, >90%, >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%, >99%) amino-acid sequence identity to these polypeptides as well as isolated nucleic acid molecules that code for these UGTs.

In one embodiment, steviol biosynthesis enzymes, UGTs and UDP-glucose recycling system are present in one microorganism (microbial cell). The microorganism may be for example, *E. coli*, *Saccharomyces* sp., *Aspergillus* sp., *Pichia* sp., *Bacillus* sp., *Yarrowia* sp.

In one embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviol or any starting steviol glycoside bearing an -OH functional group at C13 to give a target steviol glycoside having an -O-glucose beta glucopyranoside glycosidic linkage at C13. In a particular embodiment, the UDP-glucosyltransferase is UGT85C2, or a UGT having >85% amino-acid sequence identity with UGT85C2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviol or any starting steviol glycoside bearing a -COOH functional group at C19 to give a target steviol glycoside having a -COO-glucose beta-glucopyranoside glycosidic linkage at C19. In a particular embodiment, the UDP-glucosyltransferase is UGT74G1, or a UGT having >85% amino-acid sequence identity with UGT74G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to any existing glucose on the C19 side of any starting steviol glycoside to give a target steviol glycoside with at least one additional glucose bearing at least one beta 1→2 glucopyranoside glycosidic linkage(s) at the newly formed glycosidic bond(s). In a particular embodiment, the UDP-glucosyltransferase is UGTS12, or a UGT having >85% amino-acid sequence identity with UGTS12. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to any existing glucose on the C19 side of any starting steviol glycoside to give a target steviol glycoside with at least one additional glucose bearing at least one beta 1→3 glucopyranoside glycosidic linkage(s) at the newly formed bond glycosidic bond(s). In a particular embodiment, the UDP-glucosyltransferase is UGT76G1, or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to any existing glucose on

the C19 side of any starting steviol glycoside to give a target steviol glycoside with at least one additional glucose bearing at least one beta 1→4 glucopyranoside glycosidic linkage(s) at the newly formed glycosidic bond(s). In a particular embodiment, the UDP-glucosyltransferase is UGTSl2, or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In another particular embodiment, the UDP-glucosyltransferase is UGT76G1, or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to any existing glucose on the C19 side of any starting steviol glycoside to give a target steviol glycoside with at least one additional glucose bearing at least one beta 1→6 glucopyranoside glycosidic linkage(s) at the newly formed glycosidic bond(s). In a particular embodiment, the UDP-glucosyltransferase is UGTSl2, or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to any existing glucose on the C13 side of any starting steviol glycoside to give a target steviol glycoside with at least one additional glucose bearing at least one beta 1→2 glucopyranoside glycosidic linkage(s) at the newly formed glycosidic bond(s). In a particular embodiment, the UDP-glucosyltransferase is UGTSl2, or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to any existing glucose on

the C13 side of any starting steviol glycoside to give a target steviol glycoside with at least one additional glucose bearing at least one beta 1→3 glucopyranoside glycosidic linkage(s) at the newly formed bond glycosidic bond(s). In a particular embodiment, the UDP-glucosyltransferase is UGT76G1, or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to any existing glucose on the C13 side of any starting steviol glycoside to give a target steviol glycoside with at least one additional glucose bearing at least one beta 1→4 glucopyranoside glycosidic linkage(s) at the newly formed glycosidic bond(s). In a particular embodiment, the UDP-glucosyltransferase is UGTSl2, or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In another particular embodiment, the UDP-glucosyltransferase is UGT76G1, or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to any existing glucose on the C13 side of any starting steviol glycoside to give a target steviol glycoside with at least one additional glucose bearing at least one beta 1→6 glucopyranoside glycosidic linkage(s) at the newly formed glycosidic bond(s). In a particular embodiment, the UDP-glucosyltransferase is UGTSl2, or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In one embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviol to form steviolmonoside. In a particular embodiment, the UDP-glucosyltransferase is UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviol to form steviolmonoside *A*. In a particular embodiment, the UDP-glucosyltransferase is UGT74G1 or a UGT having >85% amino-acid sequence identity with UGT74G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolmonoside to form steviolbioside. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolmonoside to form steviolbioside *D*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolmonoside to form rubusoside. In a particular embodiment, the UDP-glucosyltransferase is UGT74G1 or a UGT having >85% amino-acid sequence identity with UGT74G1.

In one embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolmonoside *A* to form rubusoside. In a particular embodiment, the UDP-glucosyltransferase is UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolmonoside *A* to form steviolbioside *A*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-

glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolmonoside *A* to form steviolbioside *B*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside to form rebaudioside *B*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside to form stevioside. In a particular embodiment, the UDP-glucosyltransferase is UGT74G1 or a UGT having >85% amino-acid sequence identity with UGT74G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside *D* to form rebaudioside *B*. In a particular embodiment, the UDP-glucosyltransferase is UGTS12 or a UGT having >85% amino-acid sequence identity with UGTS12. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside *D* to form rebaudioside *G*. In a particular embodiment, the UDP-glucosyltransferase is UGT74G1 or a UGT having >85% amino-acid sequence identity with UGT74G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rubusoside to form stevioside. In a particular embodiment, the UDP-glucosyltransferase is UGTS12 or a UGT having >85% amino-acid sequence identity with UGTS12. In another particular

embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rubusoside to form rebaudioside *G*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rubusoside to form stevioside *A*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rubusoside to form stevioside *B*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In one embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside *A* to form stevioside *A*. In a particular embodiment, the UDP-glucosyltransferase is UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside *A* to form stevioside *C*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In one embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside *B* to form stevioside *B*. In a particular embodiment, the UDP-glucosyltransferase is UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside *B* to form stevioside *C*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *B* to form rebaudioside *A*. In a particular embodiment, the UDP-glucosyltransferase is UGT74G1 or a UGT having >85% amino-acid sequence identity with UGT74G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside to form rebaudioside *A*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside to form rebaudioside *E*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside to form

rebaudioside *E2*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *G* to form rebaudioside *A*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *G* to form rebaudioside *E4*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *G* to form rebaudioside *E6*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside *A* to form rebaudioside *E*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside *A* to form rebaudioside *E4*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside *A* to form rebaudioside *E3*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside *B* to form rebaudioside *E2*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside *B* to form rebaudioside *E6*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside *B* to form rebaudioside *E3*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In one embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to steviolbioside *C* to form rebaudioside *E3*. In a particular embodiment, the UDP-glucosyltransferase is UGT85C2 or a UGT having >85%

amino-acid sequence identity with UGT85C2 or a UGT having >85% amino-acid sequence identity with UGT85C2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *A* to form rebaudioside *D*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *A* to form rebaudioside *I*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E* to form rebaudioside *D*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E* to form rebaudioside *AM*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E2* to form rebaudioside *I*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E2* to form rebaudioside *AM*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular

embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E4* to form rebaudioside *D*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E4* to form rebaudioside *D7*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E6* to form rebaudioside *I*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E6* to form rebaudioside *D7*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-

glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E3* to form rebaudioside *AM*. In a particular embodiment, the UDP-glucosyltransferase is UGTS12 or a UGT having >85% amino-acid sequence identity with UGTS12. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *E3* to form rebaudioside *D7*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *D* to form rebaudioside *M*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *I* to form rebaudioside *M*. In a particular embodiment, the UDP-glucosyltransferase is UGTS12 or a UGT having >85% amino-acid sequence identity with UGTS12. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *AM* to form rebaudioside *M*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *AM* to form rebaudioside *M4*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *AM* to form rebaudioside *M5*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *D7* to form rebaudioside *M*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *1a*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-

glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *1b*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *1c*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *1d*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *1e*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *1f*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid

sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Ig*. In a particular embodiment, the UDP-glucosyltransferase is UGTSI2 or a UGT having >85% amino-acid sequence identity with UGTSI2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Ih*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Ii*. In a particular embodiment, the UDP-glucosyltransferase is UGTSI2 or a UGT having >85% amino-acid sequence identity with UGTSI2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Ij*. In a particular embodiment, the UDP-glucosyltransferase is UGTSI2 or a UGT having >85% amino-acid sequence identity with UGTSI2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Ik*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Il*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Im*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *In*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Io*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a

UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *lp*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *lq*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *lr*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity

with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *Is*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M* to form rebaudioside *It*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2a*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form

rebaudioside 2*b*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside 2*c*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside 2*d*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside 2*e*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside 2*f*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside 2g. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside 2h. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside 2i. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside 2j. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form

rebaudioside *2k*. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2l*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2m*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2n*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2o*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid

sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2p*. In a particular embodiment, the UDP-glucosyltransferase is UGTSI2 or a UGT having >85% amino-acid sequence identity with UGTSI2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2q*. In a particular embodiment, the UDP-glucosyltransferase is UGTSI2 or a UGT having >85% amino-acid sequence identity with UGTSI2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2r*. In a particular embodiment, the UDP-glucosyltransferase is UGTSI2 or a UGT having >85% amino-acid sequence identity with UGTSI2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *2s*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M4* to form rebaudioside *1q*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M5* to form rebaudioside *1m*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside *M5* to form rebaudioside *2m*. In a particular embodiment, the UDP-glucosyltransferase is UGTSl2 or a UGT having >85% amino-acid sequence identity with UGTSl2. In another particular embodiment, the UDP-glucosyltransferase is EUGT11, or a UGT having >85% amino-acid

sequence identity with EUGT11. In yet another particular embodiment, the UDP-glucosyltransferase is UGT91D2, or a UGT having >85% amino-acid sequence identity with UGT91D2. In a particular embodiment, the UDP-glucosyltransferase is UGT76G1 or a UGT having >85% amino-acid sequence identity with UGT76G1.

Optionally, the method of the present invention further comprises recycling UDP to provide UDP-glucose. In one embodiment, the method comprises recycling UDP by providing a recycling catalyst and a recycling substrate, such that the biotransformation of steviol and/or the steviol glycoside substrate to the target steviol glycoside is carried out using catalytic amounts of UDP-glucosyltransferase and UDP-glucose.

In one embodiment, the recycling catalyst is sucrose synthase SuSy_At or a sucrose synthase having >85% amino-acid sequence identity with SuSy_At.

In one embodiment, the recycling substrate for UDP-glucose recycling catalyst is sucrose.

Optionally, the method of the present invention further comprises the use of transglycosidases that use oligo- or poly-saccharides as the sugar donor to modify recipient target steviol glycoside molecules. Non-limiting examples include cyclodextrin glycosyltransferase (CGTase), fructofuranosidase, amylase, saccharase, glucosucrase, beta-h-fructosidase, beta-fructosidase, sucrase, fructosylinvertase, alkaline invertase, acid invertase, fructofuranosidase. In some embodiments, glucose and sugar(s) other than glucose, including but not limited to fructose, xylose, rhamnose, arabinose, deoxyglucose, galactose are transferred to the recipient target steviol glycosides. In one embodiment, the recipient steviol glycoside is rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, and/or rebaudioside *2s*. In another embodiment, the recipient steviol glycoside is rebaudioside

M4. In another embodiment, the recipient steviol glycoside is rebaudioside *M5*. In another embodiment, the recipient steviol glycoside is SvG7.

In another embodiment, the UDP-glucosyltransferase capable of adding at least one glucose unit to starting composition steviol glycoside has >85% amino-acid sequence identity with UGTs selected from the following listing of GenInfo identifier numbers, preferably from the group presented in Table 1, and Table 2.

397567	30680413	115480946	147798902	218193594	225443294
454245	32816174	116310259	147811764	218193942	225444853
1359905	32816178	116310985	147827151	219885307	225449296
1685003	34393978	116788066	147836230	222615927	225449700
1685005	37993665	116788606	147839909	222619587	225454338
2191136	37993671	116789315	147846163	222623142	225454340
2501497	37993675	119394507	147855977	222625633	225454342
2911049	39104603	119640480	148905778	222625635	225454473
4218003	41469414	122209731	148905999	222636620	225454475
4314356	41469452	125526997	148906835	222636621	225458362
13492674	42566366	125534279	148907340	222636628	225461551
13492676	42570280	125534461	148908935	222636629	225461556
15217773	42572855	125540090	148909182	224053242	225461558
15217796	44890129	125541516	148909920	224053386	225469538
15223396	46806235	125545408	148910082	224055535	225469540
15223589	50284482	125547340	148910154	224056138	226316457
15227766	51090402	125547520	148910612	224056160	226492603
15230017	51090594	125554547	148910769	224067918	226494221
15231757	52839682	125557592	156138791	224072747	226495389
15234056	56550539	125557593	156138797	224080189	226495945
15234195	62734263	125557608	156138799	224091845	226502400
15234196	62857204	125559566	156138803	224094703	226507980
15238503	62857206	125563266	165972256	224100653	226531147
15239523	62857210	125571055	168016721	224100657	226532094
15239525	62857212	125579728	171674071	224101569	238477377
15239543	75265643	125588307	171906258	224103105	240254512
15239937	75285934	125589492	183013901	224103633	242032615
15240305	75288884	125599469	183013903	224103637	242032621
15240534	77550661	125601477	186478321	224109218	242038423
15982889	77556148	126635837	187373030	224114583	242043290
18086351	82791223	126635845	187373042	224116284	242044836
18418378	83778990	126635847	190692175	224120552	242051252
18418380	89953335	126635863	194701936	224121288	242056217
18418382	110741436	126635867	195620060	224121296	242056219
19743740	110743955	126635883	209954691	224121300	242056663
19911201	115438196	126635887	209954719	224130358	242059339
20149064	115438785	133874210	209954725	224140703	242059341
20260654	115441237	133874212	209954733	224143404	242060922
21435782	115454819	145358033	210063105	224143406	242067411
21553613	115456047	147772508	210063107	224144306	242067413

21593514	115457492	147776893	212275846	224285244	242076258
22759895	115459312	147776894	216296854	225431707	242076396
23955910	115464719	147776895	217074506	225435532	242084750
26452040	115471069	147786916	218185693	225436321	242091005
28393204	115471071	147798900	218187075	225440041	242095206
30679796	115474009	147798901	218189427	225441116	242345159
242345161	297724601	326492035	356523945	357140904	359486938
255536859	297725463	326493430	356523957	357165849	359487055
255538228	297728331	326500410	356523959	357165852	359488135
255541676	297738632	326506816	356523961	357168415	359488708
255547075	297745347	326507826	356523963	357437837	359493630
255552620	297745348	326508394	356524387	357442755	359493632
255552622	297795735	326509445	356524403	357442757	359493634
255555343	297796253	326511261	356527181	357445729	359493636
255555361	297796257	326511866	356533209	357445731	359493815
255555363	297796261	326512412	356533852	357445733	359495856
255555365	297797587	326517673	356534718	357446799	359495858
255555369	297798502	326518800	356535480	357446805	359495869
255555373	297799226	326521124	356542996	357452779	359495871
255555377	297805988	326525567	356543136	357452781	359497638
255556812	297807499	326525957	356543932	357452783	359807261
255556818	297809125	326526607	356549841	357452787	374256637
255563008	297809127	326527141	356549843	357452789	377655465
255564074	297811403	326530093	356554358	357452791	378405177
255564531	297820040	326534036	356554360	357452797	378829085
255572878	297821483	326534312	356558606	357452799	387135070
255577901	297825217	332071132	356560333	357470367	387135072
255583249	297832276	339715876	356560599	357472193	387135078
255583253	297832280	342306012	356560749	357472195	387135092
255583255	297832518	342306016	356566018	357474295	387135094
255585664	297832520	343457675	356566169	357474493	387135098
255585666	297840825	343457677	356566173	357474497	387135100
255634688	297840827	350534960	356567761	357474499	387135134
255644801	297847402	356498085	356574704	357490035	387135136
255645821	297849372	356499771	356576401	357493567	387135174
255647456	300078590	356499777	356577660	357497139	387135176
255648275	300669727	356499779	357114993	357497581	387135184
260279126	302142947	356501328	357115447	357497671	387135186
260279128	302142948	356502523	357115451	357500579	387135188
261343326	302142950	356503180	357115453	357504663	387135190
283132367	302142951	356503184	357116080	357504691	387135192
283362112	302765302	356503295	357116928	357504699	387135194
289188052	302796334	356504436	357117461	357504707	387135282
295841350	302811470	356504523	357117463	357505859	387135284
296088529	302821107	356504765	357117829	357510851	387135294
296090415	302821679	356511113	357117839	357516975	387135298
296090524	319759260	356515120	357125059	359477003	387135300
296090526	319759266	356517088	357126015	359477998	387135302
297599503	320148814	356520732	357134488	359478043	387135304
297601531	326489963	356522586	357135657	359478286	387135312

297611791	326490273	356522588	357138503	359484299	387135314
297722841	326491131	356522590	357139683	359486936	387135316
387135318	449440433	460376293	460413408	462423864	475546199
387135320	449445896	460378310	460416351	470101924	475556485
387135322	449446454	460380744	462394387	470102280	475559699
387135324	449447657	460381726	462394433	470102858	475578293
387135326	449449002	460382093	462394557	470104211	475591753
387135328	449449004	460382095	462395646	470104264	475593742
388493506	449449006	460382754	462395678	470104266	475612072
388495496	449451379	460384935	462396388	470106317	475622476
388498446	449451589	460384937	462396389	470106357	475622507
388499220	449451591	460385076	462396419	470115448	475623787
388502176	449451593	460385872	462396542	470130404	482550481
388517521	449453712	460386018	462397507	470131550	482550499
388519407	449453714	460389217	462399998	470136482	482550740
388521413	449453716	460394872	462400798	470136484	482550999
388827901	449453732	460396139	462401217	470136488	482552352
388827903	449457075	460397862	462402118	470136492	482554970
388827907	449467555	460397864	462402237	470137933	482555336
388827909	449468742	460398541	462402284	470137937	482555478
388827913	449495638	460403139	462402416	470140422	482556454
393887637	449495736	460403141	462404228	470140426	482557289
393887646	449499880	460403143	462406358	470140908	482558462
393887649	449502786	460403145	462408262	470141232	482558508
393990627	449503471	460405998	462409325	470142008	482558547
397746860	449503473	460407578	462409359	470142010	482561055
397789318	449515857	460407590	462409777	470142012	482561555
413924864	449518643	460409128	462411467	470143607	482562795
414590349	449519559	460409134	462414311	470143939	482562850
414590661	449522783	460409136	462414416	470145404	482565074
414591157	449524530	460409459	462414476	473923244	482566269
414879558	449524591	460409461	462415526	474114354	482566296
414879559	449528823	460409463	462415603	474143634	482566307
414879560	449528825	460409465	462415731	474202268	482568689
414888074	449534021	460409467	462416307	474299266	482570049
431812559	460365546	460410124	462416920	474363119	482570572
449432064	460366882	460410126	462416922	474366157	482575121
449432066	460369823	460410128	462416923	474429346	
449433069	460369829	460410130	462416924	475432777	
449436944	460369831	460410132	462417401	475473002	
449438665	460369833	460410134	462419769	475489790	
449438667	460370755	460410213	462420317	475511330	
449440431	460374714	460411200	462423366	475516200	

Table 1

GI number	Accession	Origin
190692175	ACE87855.1	<i>Stevia rebaudiana</i>
41469452	AAS07253.1	<i>Oryza sativa</i>
62857204	BAD95881.1	<i>Ipomoea nil</i>

62857206	BAD95882.1	<i>Ipomoea purpurea</i>
56550539	BAD77944.1	<i>Bellis perennis</i>
115454819	NP_001051010.1	<i>Oryza sativa Japonica Group</i>
115459312	NP_001053256.1	<i>Oryza sativa Japonica Group</i>
115471069	NP_001059133.1	<i>Oryza sativa Japonica Group</i>
115471071	NP_001059134.1	<i>Oryza sativa Japonica Group</i>
116310985	CAH67920.1	<i>Oryza sativa Indica Group</i>
116788066	ABK24743.1	<i>Picea sitchensis</i>
122209731	Q2V6J9.1	<i>Fragaria x ananassa</i>
125534461	EAY81009.1	<i>Oryza sativa Indica Group</i>
125559566	EAZ05102.1	<i>Oryza sativa Indica Group</i>
125588307	EAZ28971.1	<i>Oryza sativa Japonica Group</i>
148907340	ABR16806.1	<i>Picea sitchensis</i>
148910082	ABR18123.1	<i>Picea sitchensis</i>
148910612	ABR18376.1	<i>Picea sitchensis</i>
15234195	NP_194486.1	<i>Arabidopsis thaliana</i>
15239523	NP_200210.1	<i>Arabidopsis thaliana</i>
15239937	NP_196793.1	<i>Arabidopsis thaliana</i>
1685005	AAB36653.1	<i>Nicotiana tabacum</i>
183013903	ACC38471.1	<i>Medicago truncatula</i>
186478321	NP_172511.3	<i>Arabidopsis thaliana</i>
187373030	ACD03249.1	<i>Avena strigosa</i>
194701936	ACF85052.1	<i>Zea mays</i>
19743740	AAL92461.1	<i>Solanum lycopersicum</i>
212275846	NP_001131009.1	<i>Zea mays</i>
222619587	EEE55719.1	<i>Oryza sativa Japonica Group</i>
224055535	XP_002298527.1	<i>Populus trichocarpa</i>
224101569	XP_002334266.1	<i>Populus trichocarpa</i>
224120552	XP_002318358.1	<i>Populus trichocarpa</i>
224121288	XP_002330790.1	<i>Populus trichocarpa</i>
225444853	XP_002281094	<i>Vitis vinifera</i>
225454342	XP_002275850.1	<i>Vitis vinifera</i>
225454475	XP_002280923.1	<i>Vitis vinifera</i>
225461556	XP_002285222	<i>Vitis vinifera</i>
225469540	XP_002270294.1	<i>Vitis vinifera</i>
226495389	NP_001148083.1	<i>Zea mays</i>
226502400	NP_001147674.1	<i>Zea mays</i>
238477377	ACR43489.1	<i>Triticum aestivum</i>
240254512	NP_565540.4	<i>Arabidopsis thaliana</i>
2501497	Q43716.1	<i>Petunia x hybrida</i>
255555369	XP_002518721.1	<i>Ricinus communis</i>
26452040	BAC43110.1	<i>Arabidopsis thaliana</i>
296088529	CBI37520.3	<i>Vitis vinifera</i>
297611791	NP_001067852.2	<i>Oryza sativa Japonica Group</i>
297795735	XP_002865752.1	<i>Arabidopsis lyrata subsp. lyrata</i>
297798502	XP_002867135.1	<i>Arabidopsis lyrata subsp. lyrata</i>
297820040	XP_002877903.1	<i>Arabidopsis lyrata subsp. lyrata</i>
297832276	XP_002884020.1	<i>Arabidopsis lyrata subsp. lyrata</i>
302821107	XP_002992218.1	<i>Selaginella moellendorffii</i>
30680413	NP_179446.2	<i>Arabidopsis thaliana</i>
319759266	ADV71369.1	<i>Pueraria montana var. lobata</i>
326507826	BAJ86656.1	<i>Hordeum vulgare subsp. Vulgare</i>
343457675	AEM37036.1	<i>Brassica rapa subsp. oleifera</i>
350534960	NP_001234680.1	<i>Solanum lycopersicum</i>
356501328	XP_003519477.1	<i>Glycine max</i>
356522586	XP_003529927.1	<i>Glycine max</i>
356535480	XP_003536273.1	<i>Glycine max</i>
357445733	XP_003593144.1	<i>Medicago truncatula</i>

357452783	XP_003596668.1	<i>Medicago truncatula</i>
357474493	XP_003607531.1	<i>Medicago truncatula</i>
357500579	XP_003620578.1	<i>Medicago truncatula</i>
357504691	XP_003622634.1	<i>Medicago truncatula</i>
359477998	XP_003632051.1	<i>Vitis vinifera</i>
359487055	XP_002271587	<i>Vitis vinifera</i>
359495869	XP_003635104.1	<i>Vitis vinifera</i>
387135134	AFJ52948.1	<i>Linum usitatissimum</i>
387135176	AFJ52969.1	<i>Linum usitatissimum</i>
387135192	AFJ52977.1	<i>Linum usitatissimum</i>
387135282	AFJ53022.1	<i>Linum usitatissimum</i>
387135302	AFJ53032.1	<i>Linum usitatissimum</i>
387135312	AFJ53037.1	<i>Linum usitatissimum</i>
388519407	AFK47765.1	<i>Medicago truncatula</i>
393887646	AFN26668.1	<i>Barbarea vulgaris subsp. arcuata</i>
414888074	DAA64088.1	<i>Zea mays</i>
42572855	NP_974524.1	<i>Arabidopsis thaliana</i>
449440433	XP_004137989.1	<i>Cucumis sativus</i>
449446454	XP_004140986.1	<i>Cucumis sativus</i>
449449004	XP_004142255.1	<i>Cucumis sativus</i>
449451593	XP_004143546.1	<i>Cucumis sativus</i>
449515857	XP_004164964.1	<i>Cucumis sativus</i>
460382095	XP_004236775.1	<i>Solanum lycopersicum</i>
460409128	XP_004249992.1	<i>Solanum lycopersicum</i>
460409461	XP_004250157.1	<i>Solanum lycopersicum</i>
460409465	XP_004250159.1	<i>Solanum lycopersicum</i>
462396388	EMJ02187.1	<i>Prunus persica</i>
462402118	EMJ07675.1	<i>Prunus persica</i>
462409359	EMJ14693.1	<i>Prunus persica</i>
462416923	EMJ21660.1	<i>Prunus persica</i>
46806235	BAD17459.1	<i>Oryza sativa Japonica Group</i>
470104266	XP_004288529.1	<i>Fragaria vesca subsp. vesca</i>
470142008	XP_004306714.1	<i>Fragaria vesca subsp. vesca</i>
475432777	EMT01232.1	<i>Aegilops tauschii</i>
51090402	BAD35324.1	<i>Oryza sativa Japonica Group</i>

Table 2

GI number	Accession	Origin	Internal reference
460409128	XP.004249992.1	<i>Solanum lycopersicum</i>	UGTSI
460386018	XP.004238697.1	<i>Solanum lycopersicum</i>	-
460409134	XP.004249995.1	<i>Solanum lycopersicum</i>	-
460410132	XP.004250485.1	<i>Solanum lycopersicum</i>	UGTSI2
460410130	XP.004250484.1	<i>Solanum lycopersicum</i>	-
460410128	XP.004250483.1	<i>Solanum lycopersicum</i>	-
460378310	XP.004234916.1	<i>Solanum lycopersicum</i>	-
209954733	BAG80557.1	<i>Lycium barbarum</i>	UGTLB
209954725	BAG80553.1	<i>Lycium barbarum</i>	-

One embodiment of the present invention is a microbial cell comprising an enzyme, i.e. an enzyme capable of converting the starting composition to the target steviol glycoside.

Accordingly, some embodiments of the present method include contacting a microorganism with a medium containing the starting composition to provide a medium comprising at least one target steviol glycoside.

The microorganism can be any microorganism possessing the necessary enzyme(s) for converting the starting composition to target steviol glycoside(s). These enzymes are encoded within the microorganism's genome.

Suitable microorganisms include, but are not limited to, *E.coli*, *Saccharomyces* sp., *Aspergillus* sp., *Pichia* sp., *Bacillus* sp., *Yarrowia* sp. etc.

In one embodiment, the microorganism is free when contacted with the starting composition.

In another embodiment, the microorganism is immobilized when contacted with the starting composition. For example, the microorganism may be immobilized to a solid support made from inorganic or organic materials. Non-limiting examples of solid supports suitable to immobilize the microorganism include derivatized cellulose or glass, ceramics, metal oxides or membranes. The microorganism may be immobilized to the solid support, for example, by covalent attachment, adsorption, cross-linking, entrapment or encapsulation.

In still another embodiment, the enzyme capable of converting the starting composition to the target steviol glycoside is secreted out of the microorganism and into the reaction medium.

The target steviol glycoside is optionally purified. Purification of the target steviol glycoside from the reaction medium can be achieved by at least one suitable method to provide a highly purified target steviol glycoside composition. Suitable methods include crystallization, separation by membranes, centrifugation, extraction (liquid or solid phase), chromatographic separation, HPLC (preparative or analytical) or a combination of such methods.

Uses

Highly purified target glycoside(s), particularly steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside

B, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 obtained according to this invention can be used “as-is” or in combination with other sweeteners, flavors, food ingredients and combinations thereof.

Non-limiting examples of flavors include, but are not limited to, lime, lemon, orange, fruit, banana, grape, pear, pineapple, mango, berry, bitter almond, cola, cinnamon, sugar, cotton candy, vanilla and combinations thereof.

Non-limiting examples of other food ingredients include, but are not limited to, acidulants, organic and amino acids, coloring agents, bulking agents, modified starches, gums, texturizers, preservatives, caffeine, antioxidants, emulsifiers, stabilizers, thickeners, gelling agents and combinations thereof.

Highly purified target glycoside(s), particularly steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*,

rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 obtained according to this invention can be prepared in various polymorphic forms, including but not limited to hydrates, solvates, anhydrous, amorphous forms and combinations thereof.

Highly purified target glycoside(s), particularly steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 obtained according to this invention may be incorporated as a high intensity natural sweetener in foodstuffs, beverages, pharmaceutical compositions, cosmetics, chewing gums, table top products, cereals, dairy products, toothpastes and other oral cavity compositions, etc.

In some embodiments, the highly purified target glycoside(s) of present invention are present in foodstuffs, beverages, pharmaceutical compositions, cosmetics, chewing gums, table top products, cereals, dairy products, toothpastes and other oral cavity compositions, etc in an amount from about 0.0001% to about 12% by weight, such as, for example, about 0.0001% by weight, about 0.0005% by weight, about 0.001% by weight, about 0.005% by weight, about 0.01% by weight, about 0.05% by weight, about 0.1% by weight, about 0.5% by weight, about 1.0% by weight, about 1.5% by weight, about 2.0% by weight, about 2.5% by weight, about 3.0% by weight, about 3.5% by weight, about 4.0% by weight, about 4.5% by weight, about 5.0% by weight, about 5.5% by weight, about 6.0% by weight, about 6.5% by weight, about 7.0% by weight, about 7.5% by weight, about 8.0% by weight, about 8.5% by weight, about 9.0% by weight, about 9.5% by weight, about

10.0% by weight, about 10.5% by weight, about 11.0% by weight, about 11.5% by weight or about 12.0% by weight.

In a particular embodiment, the sweetener is present in the beverage in an amount from about 0.0001% by weight to about 8% by weight, such as for example, from about 0.0001% by weight to about 0.0005% by weight, from about 0.0005% by weight to about 0.001% by weight, from about 0.001% by weight to about 0.005% by weight, from about 0.005% by weight to about 0.01% by weight, from about 0.01% by weight to about 0.05% by weight, from about 0.05% by weight to about 0.1% by weight, from about 0.1% by weight to about 0.5% by weight, from about 0.5% by weight to about 1% by weight, from about 1% by weight to about 2% by weight, from about 2% by weight to about 3% by weight, from about 3% by weight to about 4% by weight, from about 4% by weight to about 5% by weight, from about 5% by weight to about 6% by weight, from about 6% by weight to about 7% by weight, and from about 7% by weight to about 8% by weight.

Highly purified target glycoside(s), particularly steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* SvG7 and/or combinations thereof, obtained according to this invention, may be employed as a sweetening compound, or it may be used together with at least one naturally occurring high intensity sweeteners such as dulcoside *A*, dulcoside *B*, dulcoside *C*, dulcoside *D*, rebaudioside *A2*, rebaudioside *A3*, rebaudioside *A4*, rebaudioside *B2*, rebaudioside *C*, rebaudioside *C2*, rebaudioside *C3*, rebaudioside *C4*, rebaudioside *C5*, rebaudioside *C6*, rebaudioside *D2*, rebaudioside *D3*, rebaudioside *D4*, rebaudioside *D5*,

rebaudioside *D6*, rebaudioside *D8*, rebaudioside *E5*, rebaudioside *E7*, rebaudioside *F*, rebaudioside *F2*, rebaudioside *F3*, rebaudioside *H*, rebaudioside *H2*, rebaudioside *H3*, rebaudioside *H4*, rebaudioside *H5*, rebaudioside *H6*, rebaudioside *I2*, rebaudioside *I3*, rebaudioside *J*, rebaudioside *K*, rebaudioside *K2*, rebaudioside *KA*, rebaudioside *L*, rebaudioside *M2*, rebaudioside *M3*, rebaudioside *N*, rebaudioside *N2*, rebaudioside *N3*, rebaudioside *N4*, rebaudioside *N5*, rebaudioside *O*, rebaudioside *O2*, rebaudioside *O3*, rebaudioside *O4*, rebaudioside *Q*, rebaudioside *Q2*, rebaudioside *Q3*, rebaudioside *R*, rebaudioside *S*, rebaudioside *T*, rebaudioside *TI*, rebaudioside *U*, rebaudioside *U2*, rebaudioside *V*, rebaudioside *V2*, rebaudioside *V3*, rebaudioside *W*, rebaudioside *W2*, rebaudioside *W3*, rebaudioside *Y*, rebaudioside *Z1*, rebaudioside *Z2*, steviolbioside *C*, steviolbioside *E*, stevioside *D*, stevioside *E*, stevioside *E2*, stevioside *F*, stevioside *G*, stevioside *H*, mogrosides, brazzein, neohesperidin dihydrochalcone, glycyrrhizic acid and its salts, thaumatin, perillartine, permandulcin, mukuroziosides, baiyunoside, phlomisioside-*I*, dimethyl-hexahydrofluorene-dicarboxylic acid, abrusosides, periandrin, carnosiflosides, cyclocarioside, pterocaryosides, polypodoside *A*, brazilin, hernandulcin, phillodulcin, glycyphyllin, phlorizin, trilobatin, dihydroflavonol, dihydroquercetin-3-acetate, neoastilbin, *trans*-cinnamaldehyde, monatin, monatin salts, other indole derivative sweeteners, selliguaein *A*, hematoxylin, monellin, osladin, pterocaryoside *A*, pterocaryoside *B*, mabinlin, pentadin, miraculin, curculin, neoculin, chlorogenic acid, cynarin, Luo Han Guo sweetener, mogroside *V*, siamenoside, siratose and combinations thereof.

In a particular embodiment, steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or

SvG7 can be used in a sweetener composition comprising a compound selected from the group consisting of dulcoside *A*, dulcoside *B*, dulcoside *C*, dulcoside *D*, rebaudioside *A2*, rebaudioside *A3*, rebaudioside *A4*, rebaudioside *B2*, rebaudioside *C*, rebaudioside *C2*, rebaudioside *C3*, rebaudioside *C4*, rebaudioside *C5*, rebaudioside *C6*, rebaudioside *D2*, rebaudioside *D3*, rebaudioside *D4*, rebaudioside *D5*, rebaudioside *D6*, rebaudioside *D8*, rebaudioside *E5*, rebaudioside *E7*, rebaudioside *F*, rebaudioside *F2*, rebaudioside *F3*, rebaudioside *H*, rebaudioside *H2*, rebaudioside *H3*, rebaudioside *H4*, rebaudioside *H5*, rebaudioside *H6*, rebaudioside *I2*, rebaudioside *I3*, rebaudioside *J*, rebaudioside *K*, rebaudioside *K2*, rebaudioside *KA*, rebaudioside *L*, rebaudioside *M2*, rebaudioside *M3*, rebaudioside *N*, rebaudioside *N2*, rebaudioside *N3*, rebaudioside *N4*, rebaudioside *N5*, rebaudioside *O*, rebaudioside *O2*, rebaudioside *O3*, rebaudioside *O4*, rebaudioside *Q*, rebaudioside *Q2*, rebaudioside *Q3*, rebaudioside *R*, rebaudioside *S*, rebaudioside *T*, rebaudioside *T1*, rebaudioside *U*, rebaudioside *U2*, rebaudioside *V*, rebaudioside *V2*, rebaudioside *V3*, rebaudioside *W*, rebaudioside *W2*, rebaudioside *W3*, rebaudioside *Y*, rebaudioside *Z1*, rebaudioside *Z2*, steviolbioside *C*, steviolbioside *E*, stevioside *D*, stevioside *E*, stevioside *E2*, stevioside *F*, stevioside *G*, stevioside *H*, NSF-02, Mogroside *V*, siratose, Luo Han Guo, allulose, allose, D-tagatose, erythritol and combinations thereof.

Highly purified target glycoside(s), particularly steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 may also be used in combination with synthetic high intensity sweeteners such as sucralose, potassium acesulfame, aspartame,

alitame, saccharin, neohesperidin dihydrochalcone, cyclamate, neotame, dulcin, suosan advantame, salts thereof, and combinations thereof.

Moreover, highly purified target steviol glycoside(s) particularly steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 can be used in combination with natural sweetener suppressors such as gymnemic acid, hodulcin, ziziphin, lactisole, and others. Steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 may also be combined with various umami taste enhancers. Steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*,

rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 can be mixed with umami tasting and sweet amino acids such as glutamate, aspartic acid, glycine, alanine, threonine, proline, serine, glutamate, lysine, tryptophan and combinations thereof.

Highly purified target steviol glycoside(s) particularly, steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 can be used in combination with one or more additive selected from the group consisting of carbohydrates, polyols, amino acids and their corresponding salts, poly-amino acids and their corresponding salts, sugar acids and their corresponding salts, nucleotides, organic acids, inorganic acids, organic salts including organic acid salts and organic base salts, inorganic salts, bitter compounds, flavorants and flavoring ingredients, astringent compounds, proteins or protein

hydrolysates, surfactants, emulsifiers, flavonoids, alcohols, polymers and combinations thereof.

Highly purified target steviol glycoside(s) particularly, steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 may be combined with polyols or sugar alcohols. The term “polyol” refers to a molecule that contains more than one hydroxyl group. A polyol may be a diol, triol, or a tetraol which contain 2, 3, and 4 hydroxyl groups, respectively. A polyol also may contain more than four hydroxyl groups, such as a pentaol, hexaol, heptaol, or the like, which contain 5, 6, or 7 hydroxyl groups, respectively. Additionally, a polyol also may be a sugar alcohol, polyhydric alcohol, or polyalcohol which is a reduced form of carbohydrate, wherein the carbonyl group (aldehyde or ketone, reducing sugar) has been reduced to a primary or secondary hydroxyl group. Examples of polyols include, but are not limited to, erythritol, maltitol, mannitol, sorbitol, lactitol, xylitol, inositol, isomalt, propylene glycol, glycerol, threitol, galactitol, hydrogenated isomaltulose, reduced isomalto-oligosaccharides, reduced xylo-oligosaccharides, reduced gentio-oligosaccharides, reduced maltose syrup, reduced glucose syrup, hydrogenated starch hydrolyzates, polyglycitols and sugar alcohols or any other carbohydrates capable of being reduced which do not adversely affect the taste of the sweetener composition.

Highly purified target steviol glycoside(s), particularly steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*,

steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 may be combined with reduced calorie sweeteners such as, for example, D-tagatose, L-sugars, L-sorbose, L-arabinose and combinations thereof.

Highly purified target steviol glycoside(s), particularly steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 may also be combined with various carbohydrates. The term “carbohydrate” generally refers to aldehyde or ketone compounds substituted with multiple hydroxyl groups, of the general formula $(\text{CH}_2\text{O})_n$, wherein *n* is 3-30, as well as their oligomers and polymers. The carbohydrates of the present invention can, in addition, be substituted or deoxygenated at one or more positions. Carbohydrates, as used herein, encompass unmodified carbohydrates, carbohydrate

derivatives, substituted carbohydrates, and modified carbohydrates. As used herein, the phrases “carbohydrate derivatives”, “substituted carbohydrate”, and “modified carbohydrates” are synonymous. Modified carbohydrate means any carbohydrate wherein at least one atom has been added, removed, or substituted, or combinations thereof. Thus, carbohydrate derivatives or substituted carbohydrates include substituted and unsubstituted monosaccharides, disaccharides, oligosaccharides, and polysaccharides. The carbohydrate derivatives or substituted carbohydrates optionally can be deoxygenated at any corresponding C-position, and/or substituted with one or more moieties such as hydrogen, halogen, haloalkyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfo, mercapto, imino, sulfonyl, sulfenyl, sulfinyl, sulfamoyl, carboalkoxy, carboxamido, phosphonyl, phosphinyl, phosphoryl, phosphino, thioester, thioether, oximino, hydrazino, carbamyl, phospho, phosphonato, or any other viable functional group provided the carbohydrate derivative or substituted carbohydrate functions to improve the sweet taste of the sweetener composition.

Examples of carbohydrates which may be used in accordance with this invention include, but are not limited to, psicose, turanose, allose, tagatose, trehalose, galactose, rhamnose, various cyclodextrins, cyclic oligosaccharides, various types of maltodextrins, dextran, sucrose, glucose, ribulose, fructose, threose, arabinose, xylose, lyxose, altrose, mannose, idose, lactose, maltose, invert sugar, isotrehalose, neotrehalose, isomaltulose, erythrose, deoxyribose, gulose, idose, talose, erythrulose, xylulose, psicose, turanose, cellobiose, amylopectin, glucosamine, mannosamine, fucose, glucuronic acid, gluconic acid, glucono-lactone, abequose, galactosamine, beet oligosaccharides, isomalto-oligosaccharides (isomaltose, isomaltotriose, panose and the like), xylo-oligosaccharides (xylotriose, xylobiose and the like), xylo-terminated oligosaccharides, gentio-oligosaccharides (gentiobiose, gentiotriose, gentiotetraose and the like), sorbose, nigero-oligosaccharides, palatinose oligosaccharides, fructooligosaccharides (kestose, nystose and the like), maltotetraol, maltotriol, malto-oligosaccharides (maltotriose, maltotetraose, maltopentaose, maltohexaose, maltoheptaose and the like), starch, inulin, inulo-oligosaccharides, lactulose, melibiose, raffinose, ribose, isomerized liquid sugars such as high fructose corn syrups, coupling sugars, and soybean oligosaccharides. Additionally, the carbohydrates as used herein may be in either the D- or L-configuration.

Highly purified target steviol glycoside(s), particularly steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 obtained according to this invention can be used in combination with various physiologically active substances or functional ingredients. Functional ingredients generally are classified into categories such as carotenoids, dietary fiber, fatty acids, saponins, antioxidants, nutraceuticals, flavonoids, isothiocyanates, phenols, plant sterols and stanols (phytosterols and phytostanols); polyols; prebiotics, probiotics; phytoestrogens; soy protein; sulfides/thiols; amino acids; proteins; vitamins; and minerals. Functional ingredients also may be classified based on their health benefits, such as cardiovascular, cholesterol-reducing, and anti-inflammatory. Exemplary functional ingredients are provided in WO2013/096420, the contents of which is hereby incorporated by reference.

Highly purified target steviol glycoside(s), particularly steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*,

rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 obtained according to this invention may be applied as a high intensity sweetener to produce zero calorie, reduced calorie or diabetic beverages and food products with improved taste characteristics. It may also be used in drinks, foodstuffs, pharmaceuticals, and other products in which sugar cannot be used. In addition, highly purified target steviol glycoside(s), particularly steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 can be used as a sweetener not only for drinks, foodstuffs, and other products dedicated for human consumption, but also in animal feed and fodder with improved characteristics.

Highly purified target steviol glycoside(s), particularly steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*,

rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 obtained according to this invention may be applied as a foaming suppressor to produce zero calorie, reduced calorie or diabetic beverages and food products.

Examples of consumable products in which highly purified target steviol glycoside(s), particularly steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 may be used as a sweetening compound include, but are not limited to, alcoholic beverages such as vodka, wine, beer, liquor, and sake, etc.; natural juices; refreshing drinks; carbonated soft drinks; diet drinks; zero calorie drinks; reduced calorie drinks and foods; yogurt drinks; instant juices; instant coffee; powdered types of instant beverages; canned products; syrups; fermented soybean paste; soy sauce; vinegar; dressings; mayonnaise; ketchups; curry; soup; instant bouillon; powdered soy sauce; powdered vinegar; types of biscuits; rice biscuit; crackers; bread; chocolates; caramel; candy; chewing gum; jelly; pudding; preserved fruits and vegetables; fresh cream; jam; marmalade; flower paste; powdered milk; ice cream; sorbet; vegetables and fruits packed in bottles; canned and boiled beans; meat and foods boiled in sweetened sauce; agricultural vegetable food products; seafood; ham; sausage; fish ham; fish sausage; fish paste; deep fried fish products; dried seafood products; frozen food products; preserved seaweed; preserved meat; tobacco; medicinal products; and many others. In principle it can have unlimited applications.

Examples of consumable products in which highly purified target steviol glycoside(s), particularly steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 may be used as a flavor modifier or flavor with modifying properties include, but are not limited to, alcoholic beverages such as vodka, wine, beer, liquor, and sake, etc.; natural juices; refreshing drinks; carbonated soft drinks; diet drinks; zero calorie drinks; reduced calorie drinks and foods; yogurt drinks; instant juices; instant coffee; powdered types of instant beverages; canned products; syrups; fermented soybean paste; soy sauce; vinegar; dressings; mayonnaise; ketchups; curry; soup; instant bouillon; powdered soy sauce; powdered vinegar; types of biscuits; rice biscuit; crackers; bread; chocolates; caramel; candy; chewing gum; jelly; pudding; preserved fruits and vegetables; fresh cream; jam; marmalade; flower paste; powdered milk; ice cream; sorbet; vegetables and fruits packed in bottles; canned and boiled beans; meat and foods boiled in sweetened sauce; agricultural vegetable food products; seafood; ham; sausage; fish ham; fish sausage; fish paste; deep fried fish products; dried seafood products; frozen food products; preserved seaweed; preserved meat; tobacco; medicinal products; and many others. In principle it can have unlimited applications.

During the manufacturing of products such as foodstuffs, drinks, pharmaceuticals, cosmetics, table top products, and chewing gum, the conventional methods such as mixing, kneading, dissolution, pickling, permeation, percolation, sprinkling, atomizing, infusing and other methods may be used.

Moreover, the highly purified target steviol glycoside(s) steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 obtained in this invention may be used in dry or liquid forms.

The highly purified target steviol glycoside can be added before or after heat treatment of food products. The amount of the highly purified target steviol glycoside(s), particularly steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 depends on the purpose of usage. As discussed above, it can be added alone or in combination with other compounds.

The present invention is also directed to sweetness enhancement in beverages using steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 as a sweetness enhancer, wherein steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 is present in a concentration at or below their respective sweetness recognition thresholds.

As used herein, the term "sweetness enhancer" refers to a compound capable of enhancing or intensifying the perception of sweet taste in a composition, such as a beverage. The term "sweetness enhancer" is synonymous with the terms "sweet taste potentiator," "sweetness potentiator," "sweetness amplifier," and "sweetness intensifier."

The term “sweetness recognition threshold concentration,” as generally used herein, is the lowest known concentration of a sweet compound that is perceivable by the human sense of taste, typically around 1.0% sucrose equivalence (1.0% SE). Generally, the sweetness enhancers may enhance or potentiate the sweet taste of sweeteners without providing any noticeable sweet taste by themselves when present at or below the sweetness recognition threshold concentration of a given sweetness enhancer; however, the sweetness enhancers may themselves provide sweet taste at concentrations above their sweetness recognition threshold concentration. The sweetness recognition threshold concentration is specific for a particular enhancer and can vary based on the beverage matrix. The sweetness recognition threshold concentration can be easily determined by taste testing increasing concentrations of a given enhancer until greater than 1.0% sucrose equivalence in a given beverage matrix is detected. The concentration that provides about 1.0% sucrose equivalence is considered the sweetness recognition threshold.

In some embodiments, sweetener is present in the beverage in an amount from about 0.0001% to about 12% by weight, such as, for example, about 0.0001 % by weight, about 0.0005% by weight, about 0.001 % by weight, about 0.005% by weight, about 0.01 % by weight, about 0.05% by weight, about 0.1 % by weight, about 0.5% by weight, about 1.0% by weight, about 1.5% by weight, about 2.0% by weight, about 2.5% by weight, about 3.0% by weight, about 3.5% by weight, about 4.0% by weight, about 4.5% by weight, about 5.0% by weight, about 5.5% by weight, about 6.0% by weight, about 6.5% by weight, about 7.0% by weight, about 7.5% by weight, about 8.0% by weight, about 8.5% by weight, about 9.0% by weight, about 9.5% by weight, about 10.0% by weight, about 10.5% by weight, about 11.0% by weight, about 11.5% by weight or about 12.0% by weight.

In a particular embodiment, the sweetener is present in the beverage in an amount from about 0.0001% by weight to about 10% by weight, such as for example, from about 0.0001% by weight to about 0.0005% by weight, from about 0.0005% by weight to about 0.001% by weight, from about 0.001% by weight to about 0.005% by weight, from about 0.005% by weight to about 0.01% by weight, from about 0.01% by weight to about 0.05% by weight, from about 0.05% by weight to about 0.1% by weight, from about 0.1% by weight to about 0.5% by weight, from about 0.5% by weight to about 1% by weight, from about 1% by weight to about 2% by weight, from about 2% by weight to about 3% by weight, from about 3% by weight to about 4% by weight, from about 4% by weight to about

5% by weight, from about 5% by weight to about 6% by weight, from about 6% by weight to about 7% by weight, from about 7% by weight to about 8% by weight, from about 8% by weight to about 9% by weight, or from about 9% by weight to about 10% by weight. In a particular embodiment, the sweetener is present in the beverage in an amount from about 0.5% by weight to about 10% by weight. In another particular embodiment, the sweetener is present in the beverage in an amount from about 2% by weight to about 8% by weight.

In one embodiment, the sweetener is a traditional caloric sweetener. Suitable sweeteners include, but are not limited to, sucrose, fructose, glucose, high fructose corn syrup and high fructose starch syrup.

In another embodiment, the sweetener is erythritol.

In still another embodiment, the sweetener is a rare sugar. Suitable rare sugars include, but are not limited to, D-allose, D-psicose, D-ribose, D-tagatose, L-glucose, L-fucose, L-arabinose, D-turanose, D-leucrose and combinations thereof.

It is contemplated that a sweetener can be used alone, or in combination with other sweeteners.

In one embodiment, the rare sugar is D-allose. In a more particular embodiment, D-allose is present in the beverage in an amount of about 0.5% to about 10% by weight, such as, for example, from about 2% to about 8%.

In another embodiment, the rare sugar is D-psicose. In a more particular embodiment, D-psicose is present in the beverage in an amount of about 0.5% to about 10% by weight, such as, for example, from about 2% to about 8%.

In still another embodiment, the rare sugar is D-ribose. In a more particular embodiment, D-ribose is present in the beverage in an amount of about 0.5% to about 10% by weight, such as, for example, from about 2% to about 8%.

In yet another embodiment, the rare sugar is D-tagatose. In a more particular embodiment, D-tagatose is present in the beverage in an amount of about 0.5% to about 10% by weight, such as, for example, from about 2% to about 8%.

In a further embodiment, the rare sugar is L-glucose. In a more particular embodiment, L-glucose is present in the beverage in an amount of about 0.5% to about 10% by weight, such as, for example, from about 2% to about 8%.

In one embodiment, the rare sugar is L-fucose. In a more particular embodiment, L-fucose is present in the beverage in an amount of about 0.5% to about 10% by weight, such as, for example, from about 2% to about 8%.

In another embodiment, the rare sugar is L-arabinose. In a more particular embodiment, L-arabinose is present in the beverage in an amount of about 0.5% to about 10% by weight, such as, for example, from about 2% to about 8%.

In yet another embodiment, the rare sugar is D-turanose. In a more particular embodiment, D-turanose is present in the beverage in an amount of about 0.5% to about 10% by weight, such as, for example, from about 2% to about 8%.

In yet another embodiment, the rare sugar is D-leucrose. In a more particular embodiment, D-leucrose is present in the beverage in an amount of about 0.5% to about 10% by weight, such as, for example, from about 2% to about 8%.

The addition of the sweetness enhancer at a concentration at or below its sweetness recognition threshold increases the detected sucrose equivalence of the beverage comprising the sweetener and the sweetness enhancer compared to a corresponding beverage in the absence of the sweetness enhancer. Moreover, sweetness can be increased by an amount more than the detectable sweetness of a solution containing the same concentration of the at least one sweetness enhancer in the absence of any sweetener.

Accordingly, the present invention also provides a method for enhancing the sweetness of a beverage comprising a sweetener comprising providing a beverage comprising a sweetener and adding a sweetness enhancer selected from steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*,

rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 or a combination thereof, wherein steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7 are present in a concentration at or below their sweetness recognition thresholds.

Addition of steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*,

rebaudioside 2*p*, rebaudioside 2*q*, rebaudioside 2*r*, rebaudioside 2*s* and/or SvG7 in a concentration at or below the sweetness recognition threshold to a beverage containing a sweetener may increase the detected sucrose equivalence from about 1.0% to about 5.0%, such as, for example, about 1.0%, about 1.5%, about 2.0%, about 2.5%, about 3.0%, about 3.5%, about 4.0%, about 4.5% or about 5.0%.

The following examples illustrate preferred embodiments of the invention for the preparation of highly purified target steviol glycoside(s), particularly steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, rebaudioside *1a*, rebaudioside *1b*, rebaudioside *1c*, rebaudioside *1d*, rebaudioside *1e*, rebaudioside *1f*, rebaudioside *1g*, rebaudioside *1h*, rebaudioside *1i*, rebaudioside *1j*, rebaudioside *1k*, rebaudioside *1l*, rebaudioside *1m*, rebaudioside *1n*, rebaudioside *1o*, rebaudioside *1p*, rebaudioside *1q*, rebaudioside *1r*, rebaudioside *1s*, rebaudioside *1t*, rebaudioside *2a*, rebaudioside *2b*, rebaudioside *2c*, rebaudioside *2d*, rebaudioside *2e*, rebaudioside *2f*, rebaudioside *2g*, rebaudioside *2h*, rebaudioside *2i*, rebaudioside *2j*, rebaudioside *2k*, rebaudioside *2l*, rebaudioside *2m*, rebaudioside *2n*, rebaudioside *2o*, rebaudioside *2p*, rebaudioside *2q*, rebaudioside *2r*, rebaudioside *2s* and/or SvG7. It will be understood that the invention is not limited to the materials, proportions, conditions and procedures set forth in the examples, which are only illustrative.

EXAMPLES

EXAMPLE 1

Protein sequences of engineered enzymes used in the biocatalytic process

SEQ ID 1:

>SuSy_At, variant PM1-54-2-E05 (engineered sucrose synthase; source of WT gene: *Arabidopsis thaliana*)

MANAERMITRVHSQRERLNETLVSERNEVLALLSRVEAKGKGILQQNQII
AEFEALPEQTRKKLEGGPFFDLLKSTQEAIVLPPWVALAVRPRPGVWEYL
RVNLHALVVEELQPAEFLHFKEELVDGVKNGNFTLELDFEPFNASIPRPT
LHKYIGNGVDFLNRHLSAKLFHDKESLLPLLDFLRLHSHQGKNLMLSEKI
QNLNTLQHTLRKAEYLAELKSETLYEEFEAKFEEIGLERGWGDNAERVL
DMIRLLLDLLEAPDPSTLETFLGRVPMVFNVVILSPHGYFAQDNVLGYPD
TGGQVVYILDQVRALEIEMLRQRIKQQGLNIKPRILILTRLLPDAVGTTTCG

ERLERVYDSEYCDILRVFPFRTTEKGIVRKWISRFEVWPYLETYTEDAAVEL
 SKELNGKPDLIIGNYSDGNLVLASLLAHKLGVTQCTIAHALEKTKYPDSDI
 YWKKLDDKYHFSCQFTADIFAMNHTDFIITSTFQEIAGSKETVGQYESHT
 AFTLPGLYRVVHGIDVFDPKFNIVSPGADMSIYFPYTEEKRRRLTKFHSEI
 EELLYSDVENDEHLCLVKDKKKPILFTMARLDRVKNLSGLVEWYGKNTRL
 RELVNLVVVGDDRRESKDNEEKAEMKKMYDLIEEYKLNQFRWISSQMD
 RVRNGELYRYICDTKGAFVQPALYEAFLTVVEAMTCGLPTFATCKGGPA
 EIIIVHGKSGFHIDPYHGDQAADLLADFFTKCKEDPSHWDEISKGGLQRIE
 EKYTWQIYSQRLTLTGVIYGFVKHVSNDRLLEHRRYLEMFYALKYRPLAQ
 AVPLAQDD

SEQ ID 2:

>UGTS12 variant 0234 (engineered glucosyltransferase; source of WT gene: *Solanum lycopersicum*)

MATNLRVLMFPWLAYGHISPFNLIAKQLADRGFLIYLCSTRINLESIKK
 IPEKYADSIHLIELQLPELPELPPHYHTTNGLPPLNPTLHKALKMSKPN
 FSRILQNLKPDLLIYDVLQPWAEHVANEQGIPAGKLLVSCAAVFSYFFSF
 RKNPGVEFFPFAIHLPEVEKVKIREILAKEPEEGGRLDEGNKQMLMCTS
 RTIEAKYIDYCTELCNWKVVPVGPPFQDLITNDADNKELIDWLGTKPENS
 TVFVSFGSEYFLSKEDMEEIAFALEASNVNFIWVVRFPKGEERNLEDALP
 EGFLERIGERGRVLDKFAPQPRI LNHPSTGGFISHCGWNSVMESIDFGVP
 IIAMPIHNDQPINAKLMVELGVAVEIVRDDDGIHRGEIAEALKSVVTGE
 TGEILRAKVREISKNLKSIRDEEMDAVAEELIQLCRNSNKS

SEQ ID 3:

>UGT76G1 variant 0042 (engineered glucosyltransferase; source of WT gene: *Stevia rebaudiana*)

MENKTETTVRRRRRIILFPVPFQGHINPILQLANVLYSKGFAITILHTNFNKPKTSNYPH
 FTFRFILDNDPQDERISNLP THGPLAGMRIPI INEHGADELRRLELEMLLASEEDEEVSC
 LITDALWYFAQDVADSLNLRRLVLMTSSLFNFHAHVSLPQFDELGYLDPDDKTRLEEQAS
 GFPM LKVKDIKSAYS NWQIGKEILGKMIKQTKASSGVIWNSFKELEESELETVIREIPAP
 SFLIPLPKHLTASSSSLLDHDRTVFEWLDQQAPSSVLYVSFGSTSEVDEKDFLEIARGLV
 DSGQSFLWVVRPGFVKGSTWVEPLPDGFLGERGKIVKWVPQQEVLAHPAIGAFWTHSGWN
 STLESVCEGVPMIFSSFGGDQPLNARYMSDVLRVGVYLENGWERGEVVAIRRMVDEEG
 EYIRQNARVLKQKADVSLMKGGSSYESLESLSVSYISL

EXAMPLE 2

Expression and formulation of SuSy_At variant of SEQ ID 1

The gene coding for the SuSy_At variant of SEQ ID 1 (EXAMPLE 1) was cloned into the expression vector pLE1A17 (derivative of pRSF-1b, Novagen). The resulting plasmid was used for transformation of *E.coli* BL21(DE3) cells.

Cells were cultivated in ZYM505 medium (F. William Studier, Protein Expression and Purification 41 (2005) 207-234) supplemented with kanamycin (50 mg/l) at 37°C. Expression of the genes was induced at logarithmic phase by IPTG (0.2 mM) and carried out at 30°C and 200 rpm for 16-18 hours.

Cells were harvested by centrifugation (3220 x g, 20 min, 4°C) and re-suspended to an optical density of 200 (measured at 600nm (OD₆₀₀)) with cell lysis buffer (100 mM Tris-HCl pH 7.0; 2 mM MgCl₂, DNA nuclease 20 U/mL, lysozyme 0.5 mg/mL). Cells were then disrupted by sonication and crude extracts were separated from cell debris by centrifugation (18000 x g 40 min, 4°C). The supernatant was sterilized by filtration through a 0.2 µm filter and diluted 50:50 with distilled water, resulting in an enzymatic active preparation.

For enzymatic active preparations of SuSy_At, activity in Units is defined as follows: 1 mU of SuSy_At turns over 1 nmol of sucrose into fructose in 1 minute. Reaction conditions for the assay are 30°C, 50 mM potassium phosphate buffer pH 7.0, 400 mM sucrose at t₀, 3 mM MgCl₂, and 15 mM uridine diphosphate (UDP).

EXAMPLE 3

Expression and formulation of UGTSl2 variant of SEQ ID 2

The gene coding for the UGTSl2 variant of SEQ ID 2 (EXAMPLE 1) was cloned into the expression vector pLE1A17 (derivative of pRSF-1b, Novagen). The resulting plasmid was used for transformation of *E.coli* BL21(DE3) cells.

Cells were cultivated in ZYM505 medium (F. William Studier, Protein Expression and Purification 41 (2005) 207-234) supplemented with kanamycin (50 mg/l) at 37°C. Expression of the genes was induced at logarithmic phase by IPTG (0.1 mM) and carried out at 30°C and 200 rpm for 16-18 hours.

Cells were harvested by centrifugation (3220 x g, 20 min, 4°C) and re-suspended to an optical density of 200 (measured at 600nm (OD₆₀₀)) with cell lysis buffer (100 mM Tris-HCl pH 7.0; 2 mM MgCl₂, DNA nuclease 20 U/mL, lysozyme 0.5 mg/mL). Cells were then disrupted by sonication and crude extracts were separated from cell debris by centrifugation (18000 x g 40 min, 4°C). The supernatant was sterilized by filtration through a 0.2 µm filter and diluted 50:50 with 1 M sucrose solution, resulting in an enzymatic active preparation.

For enzymatic active preparations of UGTSl2, activity in Units is defined as follows: 1 mU of UGTSl2 turns over 1 nmol of rebaudioside A (Reb A) into rebaudioside D (Reb D) in 1 minute. Reaction conditions for the assay are 30°C, 50 mM potassium phosphate buffer

pH 7.0, 10 mM Reb *A* at t_0 , 500 mM sucrose, 3 mM MgCl₂, 0.25 mM uridine diphosphate (UDP) and 3 U/mL of SuSy_At.

EXAMPLE 4

Expression and formulation of UGT76G1 variant of SEQ ID 3

The gene coding for the UGT76G1 variant of SEQ ID 3 (EXAMPLE 1) was cloned into the expression vector pLE1A17 (derivative of pRSF-1b, Novagen). The resulting plasmid was used for transformation of *E.coli* BL21(DE3) cells.

Cells were cultivated in ZYM505 medium (F. William Studier, Protein Expression and Purification 41 (2005) 207-234) supplemented with kanamycin (50 mg/l) at 37°C. Expression of the genes was induced at logarithmic phase by IPTG (0.1 mM) and carried out at 30°C and 200 rpm for 16-18 hours.

Cells were harvested by centrifugation (3220 x g, 20 min, 4°C) and re-suspended to an optical density of 200 (measured at 600nm (OD₆₀₀)) with cell lysis buffer (100 mM Tris-HCl pH 7.0; 2 mM MgCl₂, DNA nuclease 20 U/mL, lysozyme 0.5 mg/mL). Cells were then disrupted by sonication and crude extracts were separated from cell debris by centrifugation (18000 x g 40 min, 4°C). The supernatant was sterilized by filtration through a 0.2 µm filter and diluted 50:50 with 1 M sucrose solution, resulting in an enzymatic active preparation.

For enzymatic active preparations of UGT76G1, activity in Units is defined as follows: 1 mU of UGT76G1 turns over 1 nmol of rebaudioside *D* (Reb *D*) into rebaudioside *M* (Reb *M*) in 1 minute. Reaction conditions for the assay are 30°C, 50 mM potassium phosphate buffer pH 7.0, 10 mM Reb *D* at t_0 , 500 mM sucrose, 3 mM MgCl₂, 0.25 mM uridine diphosphate (UDP) and 3 U/mL of SuSy_At.

EXAMPLE 5

Synthesis of SvG7 in a one-pot reaction, adding UGTSl2, SuSy_At and UGT76G1 at the same time.

Various SvG7 molecules were synthesized directly from stevioside (see Fig. 12a) in a one-pot reaction, utilizing the three enzymes (see EXAMPLES 1, 2, 3 and 4): UGTSl2 (variant of SEQ ID 2), SuSy_At (variant of SEQ ID 1) and UGT76G1 (variant of SEQ ID 3).

The final reaction solution contained 348 U/L UGTSl2, 1341 U/L SuSy_At, 10 U/L UGT76G1, 47 mM stevioside, 0.32 mM uridine diphosphate (UDP), 0.99 M sucrose, 3.9

mM MgCl₂ and potassium phosphate buffer (pH 6.6). First, 206 mL of distilled water were mixed with 0.24 g MgCl₂·6H₂O, 102 g sucrose, 9.8 mL of 1.5 M potassium phosphate buffer (pH 6.6) and 15 g stevioside. The final volume of the reaction mixture was adjusted to 300 mL.

After dissolving the components, the temperature was adjusted to 45 °C and UGTS12, SuSy_At, UGT76G1 and 39 mg UDP were added. The reaction mixture was incubated at 45°C shaker for 24 hrs. Additional 39 mg UDP was added at 12 hours, 24 hours, and 36 hours. The content of reb *M5*, reb *2a*, reb *2m* and various SvG7 at the end of the reaction (48 hours) was analyzed by HPLC.

EXAMPLE 6

HPLC Analysis

For analysis, biotransformation samples were inactivated by adjusting the reaction mixture to pH5.5 using 17% H₃PO₄ and then boiled for 10 minutes. Resulting samples were filtered, the filtrates were diluted 10 times and used as samples for HPLC analysis. HPLC assay was carried out on Agilent HP 1200 HPLC system, comprised of a pump, a column thermostat, an auto sampler, a UV detector capable of background correction and a data acquisition system. Analytes were separated using Agilent Poroshell 120 SB- C18, 4.6 mm x 150 mm, 2.7 µm at 40°C. The mobile phase consisted of two premixes:

- premix 1 containing 75% 10 mM phosphate buffer (pH2.6) and 25% acetonitrile, and
- premix 2 containing 68% 10 mM phosphate buffer (pH2.6) and 32% acetonitrile.

Elution gradient started with premix 1, changed to premix 2 to 50% at 12.5 minute, changed to premix 2 to 100% at 13 minutes. Total run time was 45 minutes. The column temperature was maintained at 40 °C. The injection volume was 5 µL. Rebaudioside species were detected by UV at 210 nm.

Table 3 shows for each time point the conversion of stevioside into identified rebaudioside species (area percentage). The chromatograms of the starting material stevioside and the reaction mixture at 48 hours are shown in Fig. 12a and Fig. 12b respectively. Those with skill in the art will appreciate that retention times can occasionally vary with changes in solvent and/or equipment.

Table 3

Biotransformation of stevioside to reb *M5* (rt 5.350), reb *2a* (rt 6.459), reb *2m* (rt 5.089) and various SvG7

Peak	% conversion from stevioside	
	reaction time 0 hr	reaction time 48 hr
rt 2.651	0	0.83
rt 2.874	0	6.79
rt 3.275	0	0.15
rt 3.570	0	0.05
rt 3.798	0	0.18
rt 4.279	0	0.08
rt 4.477	0	0.05
rt 4.798	0	0.04
rt 5.089	0	0.68
rt 5.350	0	0.86
rt 5.758	0	0.28
rt 5.896	0	1.06
rt 6.261	0	0.22
rt 6.459	0	1.37
rt 6.842	0	0.57
rt 7.952	0	0.5
rt 8.775	0	1.07
reb <i>AM</i>	0	65.7
rt 10.346	0	0.83
rt 11.217	0	0.54
rt 12.425	0	0.2
reb <i>M</i>	0	14.97
rt 15.174	0	0.4
reb <i>A</i>	12.97	0
stevioside	82.83	0
reb <i>B</i>	0.38	1.47
steviolbioside	3.82	1.11

EXAMPLE 7

Purification of rebaudiosides *M5*, *2a*, *2m* and various SvG7

300 mL of the reaction mixture of EXAMPLE 5, (after 48 hrs), was inactivated by adjusting the pH to pH 5.5 with H₃PO₄ and then boiled for 10 minutes and filtered. The filtrate was loaded into a column containing 500 mL YWD03 (Cangzhou Yuanwei, China) resin pre-equilibrated with water. The resin was washed with 2.5 L water and the water effluent from this step was discarded.

The steviol glycosides were eluted from the YWD03 resin column by elution with 2.5 L 70 % v/v ethanol/water. The effluent from this step was collected and dried under

vacuum at 60°C to yield 20g of dried solid product. This sample was dissolved in water and subjected to further fractionation and separation by HPLC, using the conditions listed in Table 4 below.

HPLC fractions that corresponded to individual compounds from multiple runs were combined according to retention time. The fractions were freeze-dried.

Table 4
Conditions for HPLC

Column	Agilent Prodigy 3u ODS(3) 100A, 4.6mm x 250mm, 3 micron
Temperature	40 °C
Mobile Phase	Isocratic – Water 77% Acetonitrile 23%
Flow rate	0.5 mL/min
Injection	10 µL
Stop time	45 mins
Autosampler temperature	Ambient
Detection	UV at 210 nm


The purity of obtained fractions was evaluated by analytical HPLC method described in EXAMPLE 6. The chromatogram of purified rebaudioside *2a* is shown in Fig. 12c. The chromatogram of purified rebaudioside *2m* is shown in Fig. 12d. The chromatogram of purified rebaudioside *M5* is shown in Fig. 12e.

EXAMPLE 8

Structure elucidation of rebaudioside *2a*

NMR experiments were performed on a Bruker 500 MHz spectrometer, with the sample dissolved in pyridine-*d*₅. Along with signals from the sample, signals from pyridine-*d*₅ at δ_C 123.5, 135.5, 149.9 ppm and δ_H 7.19, 7.55, 8.71 ppm were observed. ¹H-NMR spectrum of rebaudioside *2a* recorded in pyridine-*d*₅ confirmed the excellent quality of the sample (see Fig. 13a). HSQC (see Fig. 13b) shows the presence of an exomethylene group in the sugar region with a long-range coupling to C-15, observable in the H,H-COSY (Fig. 13c). Other deep-fielded signals of the quaternary carbons (C-13, C-16 and C-19) are detected by the HMBC (Fig. 13d). Correlation of the signals in the HSQC,

HMBC and ^1H , ^1H -COSY reveal the presence of steviol glycoside with the following aglycone structure:



Correlation of HSQC and HMBC shows the presence seven anomeric signals, marked with 1i, 1ii, 1iii, 1iv, 1v, 1vi and 1vii. The coupling constant of the anomeric protons of about 8 Hz, the broad signals of their sugar linkage and the NOE-correlations of the anomeric protons allow the identification of these seven sugars as β -D-glucopyranosides.

Combined data from HSQC and HMBC reveal the sugar-sugar linkages and sugar-aglycone linkages. The assignment of the sugar sequence was confirmed by using the combination of HSQC-TOCSY (Fig. 13e) and NOESY (Fig. 13f).

Altogether, results from NMR experiments above were used to assign the chemical shifts of the protons and carbons of the structure of rebaudioside 2a (see Table 5).

Table 5
Chemical shifts of rebaudioside 2a

Position	δ_C [ppm]		δ_H [ppm]		J [Hz]/ (INT)	HMBC (H -> C)
Aglycone moiety						
1	40.1	<i>t</i>	0.67 1.62	<i>m</i> <i>m</i>		
2	19.5	<i>t</i>	1.36 2.10	<i>m</i> <i>m</i>		
3	37.1	<i>t</i>	1.05 2.77	<i>m</i> <i>m</i>		
4	44.5	<i>s</i>	-			
5	57.1	<i>d</i>	0.94	<i>m</i>		
6	21.8	<i>t</i>	1.92 2.13	<i>m</i> <i>m</i>		
7	40.9	<i>t</i>	1.22 1.36	<i>m</i> <i>m</i>		
8	42.1	<i>s</i>	-			
9	53.4	<i>d</i>	0.82	<i>m</i>		
10	39.1	<i>s</i>	-			
11	20.4	<i>t</i>	1.57 1.60	<i>m</i> <i>m</i>		
12	37.4	<i>t</i>	1.90 2.13	<i>m</i> <i>m</i>		
13	86.5	<i>s</i>	-			
14	43.4	<i>t</i>	1.77 2.47	<i>d</i> <i>d</i>	11.1 11.1	
15	47.2	<i>t</i>	1.96 1.99	<i>d</i> <i>d</i>	16.0 16.0	7, 8, 9, 14
16	153.7	<i>s</i>	-			
17	104.4	<i>t</i>	4.99 5.67	<i>br s</i> <i>br s</i>		13, 15, 16
18	28.5	<i>q</i>	1.40	<i>s</i>	(3H)	3, 4, 5, 19
19	175.7	<i>s</i>	-			
20	16.0	<i>q</i>	1.04	<i>s</i>	(3H)	1, 5, 9, 10


Table 5 (continued)
Chemical shifts of rebaudioside 2a

Position	δ_C [ppm]		δ_H [ppm]		J [Hz]/ (Int)	HMBC (H $\rightarrow$ C)	NOE (H $\rightarrow$ H)
Sugar moiety							
Sugar I: β -D-Glucopyranoside							
1 ⁱ	97.0	<i>d</i>	5.09	<i>d</i>	7.7	13	
2 ⁱ	81.9	<i>d</i>	4.16	<i>m</i>			
3 ⁱ	75.8	<i>d</i>	4.37	<i>m</i>			
4 ⁱ	81.9	<i>d</i>	3.85	<i>m</i>			
5 ⁱ	75.6	<i>d</i>	3.97	<i>m</i>			
6 ⁱ	61.8	<i>t</i>	4.20 4.80	<i>m</i> <i>m</i>			
Sugar II: β -D-Glucopyranoside							
1 ⁱⁱ	105.0	<i>d</i>	5.28	<i>d</i>	8.0	2 ⁱ	2 ⁱ
2 ⁱⁱ	76.3	<i>d</i>	4.09	<i>m</i>			
3 ⁱⁱ	78.0	<i>d</i>	4.29	<i>m</i>			
4 ⁱⁱ	70.8	<i>d</i>	4.24	<i>m</i>			
5 ⁱⁱ	78.1	<i>d</i>	3.91	<i>m</i>			
6 ⁱⁱ	61.4	<i>t</i>	4.39 4.50	<i>m</i> <i>m</i>			
Sugar III: β -D-Glucopyranoside							
1 ⁱⁱⁱ	102.4	<i>d</i>	4.98	<i>d</i>	8.1	4 ⁱ	4 ⁱ
2 ⁱⁱⁱ	84.8	<i>d</i>	4.05	<i>m</i>			
3 ⁱⁱⁱ	77.9	<i>d</i>	4.22	<i>m</i>			
4 ⁱⁱⁱ	70.9	<i>d</i>	4.12	<i>m</i>			
5 ⁱⁱⁱ	77.6	<i>d</i>	3.92	<i>m</i>			
6 ⁱⁱⁱ	62.5	<i>t</i>	4.31 4.53	<i>m</i> <i>m</i>			
Sugar IV: β -D-Glucopyranoside							
1 ^{iv}	106.4	<i>d</i>	5.22	<i>d</i>	7.8	2 ⁱⁱⁱ	2 ⁱⁱⁱ
2 ^{iv}	76.1	<i>d</i>	4.12	<i>m</i>			
3 ^{iv}	78.1	<i>d</i>	4.06	<i>m</i>			
4 ^{iv}	70.4	<i>d</i>	4.25	<i>m</i>			
5 ^{iv}	78.3	<i>d</i>	3.81	<i>m</i>			
6 ^{iv}	61.6	<i>t</i>	4.24 4.50	<i>m</i> <i>m</i>			
Sugar V: β -D-Glucopyranoside							
1 ^v	93.0	<i>d</i>	6.25	<i>d</i>	8.1	19	
2 ^v	76.8	<i>d</i>	4.47	<i>m</i>			
3 ^v	88.2	<i>d</i>	4.28	<i>m</i>			
4 ^v	69.1	<i>d</i>	4.12	<i>m</i>			
5 ^v	78.2	<i>d</i>	3.92	<i>m</i>			
6 ^v	61.5	<i>t</i>	4.16 4.33	<i>m</i> <i>m</i>			

Table 5 (continued)
Chemical shifts of rebaudioside *2a*

Position	δ_c [ppm]	δ_H [ppm]	J [Hz]/ (Int)	HMBC (H $\rightarrow$ C)	NOE (H $\rightarrow$ H)
<i>Sugar moiety</i>					
Sugar VI: β -D-Glucopyranoside					
1 ^{vi}	103.5	<i>d</i>	5.77	<i>d</i>	7.8
2 ^{vi}	75.4	<i>d</i>	4.00	<i>m</i>	
3 ^{vi}	77.6	<i>d</i>	4.27	<i>m</i>	
4 ^{vi}	71.1	<i>d</i>	4.27	<i>m</i>	
5 ^{vi}	78.0	<i>d</i>	3.96	<i>m</i>	
6 ^{vi}	62.7	<i>t</i>	4.42 4.58	<i>m</i> <i>m</i>	
Sugar VII: β -D-Glucopyranoside					
1 ^{vii}	104.4	<i>d</i>	5.28	<i>d</i>	8.0
2 ^{vii}	75.0	<i>d</i>	4.01	<i>m</i>	
3 ^{vii}	77.2	<i>d</i>	4.17	<i>m</i>	
4 ^{vii}	71.5	<i>d</i>	4.10	<i>m</i>	
5 ^{vii}	77.9	<i>d</i>	4.00	<i>m</i>	
6 ^{vii}	61.8	<i>t</i>	4.42 4.52	<i>m</i> <i>m</i>	

Correlation of all NMR results indicates rebaudioside *2a* with seven β -D-glucoses attached to steviol aglycone, as depicted with the following chemical structure:



LCMS (Fig. 13g and Fig. 13h) analysis of rebaudioside *2a* showed a $[M-H]^-$ ion at m/z 1451.6, in good agreement with the expected molecular formula of $C_{62}H_{100}O_{38}$ (calculated for $[C_{62}H_{99}O_{38}]^-$ monoisotopic ion: 1451.6). The MS data confirms that rebaudioside *2a* has a molecular formula of $C_{62}H_{100}O_{38}$. LCMS analysis was performed in the following conditions listed in Table 6.


Table 6
Conditions for LCMS analysis

Column	Agilent Poroshell 120 SB-C18, 4.6mm x 150mm, 2.7 μ m		
Temperature	40°C		
Mobile Phase	A: Mobile Phase Premix Solution - 25 % Acetonitrile : 75 % Formic Acid (0.1% in Water) B: Mobile Phase Premix Solution - 32 % Acetonitrile : 68 % Formic Acid (0.1% in Water)		
Gradient	Time (min)	A (%)	B (%)
	0	100	0
	12.0	100	0
	12.5	50	50
	13.0	0	100
	60.0	0	100
Flow rate	0.5 mL/min		
Injection	2 μ L		
Run time	45 mins		
Post time	5 mins		
Autosampler temperature	Ambient		
Detection	MSD at Negative Scan mode		
MSD Setting	Mode : ES-API, Negative Polarity Drying gas flow : 13.0 L/min Nebulizer Pressure : 30 psig Drying gas temperature : 270°C Fragmentor : 50V Scan ranges : 500 to 1500 of mass		
Sample Preparation	1 mg/ml (30% ACN in water)		

EXAMPLE 9

Structure elucidation of rebaudioside *2m*

NMR experiments were performed on a Bruker 500 MHz spectrometer, with the sample dissolved in pyridine-*d*₅. Along with signals from the sample, signals from pyridine-*d*₅ at δ_C 123.5, 135.5, 149.9 ppm and δ_H 7.19, 7.55, 8.71 ppm were observed. ¹H-NMR spectrum of rebaudioside *2m* recorded in pyridine-*d*₅ confirmed the excellent quality of the sample (see Fig. 14a). HSQC (see Fig. 14b) shows the presence of an exomethylene group in the sugar region with a long-range coupling to C-15, observable in the H,H-COSY (Fig. 14c). Other deep-fielded signals of the quaternary carbons (C-13, C-16 and C-19) are detected by the HMBC (Fig. 14d). Correlation of the signals in the HSQC, HMBC and H,H-COSY reveal the presence of steviol glycoside with the following aglycone structure:



Correlation of HSQC and HMBC shows the presence seven anomeric signals, marked with 1i, 1ii, 1iii, 1iv, 1v, 1vi and 1vii. The coupling constant of the anomeric protons of about 8 Hz, the broad signals of their sugar linkage and the NOE-correlations of the anomeric protons allow the identification of these seven sugars as β -D-glucopyranosides.

Combined data from HSQC and HMBC reveal the sugar-sugar linkages and sugar-aglycone linkages. The assignment of the sugar sequence was confirmed by using the combination of HSQC-TOCSY (Fig. 14e) and NOESY (Fig. 14f).

Altogether, results from NMR experiments above were used to assign the chemical shifts of the protons and carbons of the structure of rebaudioside *2m* (see Table 7).

Table 7
Chemical shifts of rebaudioside 2*m*

Position	δ_C [ppm]		δ_H [ppm]		J [Hz]/ (INT)	HMBC (H -> C)
<i>Aglycone moiety</i>						
1	40.0	<i>t</i>	0.68 1.63	<i>m</i> <i>m</i>		
2	19.3	<i>t</i>	1.38 2.06	<i>m</i> <i>m</i>		
3	37.1	<i>t</i>	1.04 2.81	<i>m</i> <i>m</i>		
4	44.0	<i>s</i>	-			
5	56.9	<i>d</i>	0.96	<i>m</i>		
6	21.8	<i>t</i>	1.93 2.13	<i>m</i> <i>m</i>		
7	41.1	<i>t</i>	1.25 1.36	<i>m</i> <i>m</i>		
8	41.6	<i>s</i>	-			
9	53.6	<i>d</i>	0.82	<i>m</i>		
10	40.4	<i>s</i>	-			
11	19.8	<i>t</i>	1.58 1.61	<i>m</i> <i>m</i>		
12	37.5	<i>t</i>	1.96 1.99	<i>m</i> <i>m</i>		
13	86.2	<i>s</i>	-			
14	43.1	<i>t</i>	1.73 2.34	<i>d</i> <i>d</i>	10.9 10.9	
15	47.5	<i>t</i>	1.96 2.02	<i>d</i> <i>d</i>	15.9 15.9	7, 8, 9, 14
16	153.4	<i>s</i>	-			
17	104.3	<i>t</i>	4.98 5.55	<i>br s</i> <i>br s</i>		13, 15, 16
18	28.6	<i>q</i>	1.42	<i>s</i>	(3H)	3, 4, 5, 19
19	175.3	<i>s</i>	-			
20	16.3	<i>q</i>	1.01	<i>s</i>	(3H)	1, 5, 9, 10


Table 7 (continued)
Chemical shifts of rebaudioside 2*m*

Position	δ_C [ppm]	δ_H [ppm]			J [Hz]/ (Int)	HMBC (H $\rightarrow$ C)	NOE (H $\rightarrow$ H)
Sugar moiety							
Sugar I: β -D-Glucopyranoside							
1 ⁱ	97.3	<i>d</i>	4.88	<i>d</i>	7.8	13	3 ⁱ , 5 ⁱ
2 ⁱ	81.9	<i>d</i>	3.75	<i>m</i>			
3 ⁱ	75.3	<i>d</i>	4.18	<i>m</i>			
4 ⁱ	79.6	<i>d</i>	4.40	<i>m</i>			
5 ⁱ	74.0	<i>d</i>	3.50	<i>m</i>			
6 ⁱ	67.9	<i>t</i>	4.55	<i>m</i>	(2H)		5 ⁱ , 1 ^{iv}
Sugar II: β -D-Glucopyranoside							
1 ⁱⁱ	105.7	<i>d</i>	5.10	<i>d</i>	8.0	2 ⁱ	2 ⁱ , 3 ⁱⁱ , 5 ⁱⁱ
2 ⁱⁱ	74.6	<i>d</i>	4.02	<i>m</i>			
3 ⁱⁱ	77.9	<i>d</i>	4.18	<i>m</i>			
4 ⁱⁱ	71.4	<i>d</i>	4.20	<i>m</i>			
5 ⁱⁱ	78.1	<i>d</i>	3.87	<i>m</i>			
6 ⁱⁱ	61.8	<i>t</i>	4.19 4.46	<i>m</i> <i>m</i>			
Sugar III: β -D-Glucopyranoside							
1 ⁱⁱⁱ	104.3	<i>d</i>	5.57	<i>d</i>	8.1	4 ⁱ	4 ⁱ , 3 ⁱⁱⁱ , 5 ⁱⁱⁱ
2 ⁱⁱⁱ	75.2	<i>d</i>	4.03	<i>m</i>			
3 ⁱⁱⁱ	77.1	<i>d</i>	4.35	<i>m</i>			
4 ⁱⁱⁱ	71.4	<i>d</i>	4.23	<i>m</i>			
5 ⁱⁱⁱ	76.8	<i>d</i>	4.19	<i>m</i>			
6 ⁱⁱⁱ	63.3	<i>t</i>	4.34 4.56	<i>m</i> <i>m</i>			
Sugar IV: β -D-Glucopyranoside							
1 ^{iv}	104.9	<i>d</i>	5.37	<i>d</i>	8.0	6 ⁱ	6 ⁱ , 3 ^{iv} , 5 ^{iv}
2 ^{iv}	75.0	<i>d</i>	4.06	<i>m</i>			
3 ^{iv}	78.3	<i>d</i>	4.29	<i>m</i>			
4 ^{iv}	71.1	<i>d</i>	4.27	<i>m</i>			
5 ^{iv}	78.0	<i>d</i>	3.99	<i>m</i>			
6 ^{iv}	62.1	<i>t</i>	4.22 4.36	<i>m</i> <i>m</i>			
Sugar V: β -D-Glucopyranoside							
1 ^v	92.8	<i>d</i>	6.27	<i>d</i>	8.1	19	3 ^v , 5 ^v
2 ^v	77.0	<i>d</i>	4.47	<i>m</i>			
3 ^v	88.2	<i>d</i>	4.28	<i>m</i>			
4 ^v	69.0	<i>d</i>	4.10	<i>m</i>			
5 ^v	78.1	<i>d</i>	3.88	<i>m</i>			
6 ^v	61.7	<i>t</i>	4.22 4.36	<i>m</i> <i>m</i>			

Table 7 (continued)
Chemical shifts of rebaudioside *2m*

Position	δ_{C} [ppm]	δ_{H} [ppm]	J [Hz]/ (Int)		HMBC (H $\rightarrow$ C)	NOE (H $\rightarrow$ H)	
<i>Sugar moiety</i>							
Sugar VI: β -D-Glucopyranoside							
1 ^{vi}	103.2	<i>d</i>	5.78	<i>d</i>	7.8	2 ^v	2 ^v , 3 ^{vi} , 5 ^{vi}
2 ^{vi}	75.6	<i>d</i>	3.99	<i>m</i>			
3 ^{vi}	78.2	<i>d</i>	4.25	<i>m</i>			
4 ^{vi}	72.7	<i>d</i>	4.10	<i>m</i>			
5 ^{vi}	78.0	<i>d</i>	3.93	<i>m</i>			
6 ^{vi}	62.6	<i>t</i>	4.29 4.40	<i>m</i> <i>m</i>			
Sugar VII: β -D-Glucopyranoside							
1 ^{vii}	104.4	<i>d</i>	5.30	<i>d</i>	8.0	3 ^v	3 ^v , 3 ^{vii} , 5 ^{vii}
2 ^{vii}	75.3	<i>d</i>	4.00	<i>m</i>			
3 ^{vii}	78.1	<i>d</i>	4.12	<i>m</i>			
4 ^{vii}	71.2	<i>d</i>	4.12	<i>m</i>			
5 ^{vii}	78.1	<i>d</i>	3.97	<i>m</i>			
6 ^{vii}	62.0	<i>t</i>	4.26 4.46	<i>m</i> <i>m</i>			

Correlation of all NMR results indicates rebaudioside *2m* with seven β -D-glucoses attached to steviol aglycone, as depicted with the following chemical structure:




LCMS (Fig. 14g and Fig. 14h) analysis of rebaudioside *2m* showed a $[M-H]^-$ ion at m/z 1451.6, in good agreement with the expected molecular formula of $C_{62}H_{100}O_{38}$ (calculated for $[C_{62}H_{99}O_{38}]^-$ monoisotopic ion: 1451.6). The MS data confirms that rebaudioside *2m* has a molecular formula of $C_{62}H_{100}O_{38}$. LCMS analysis was performed in the conditions listed in Table 6.

EXAMPLE 10

Structure elucidation of rebaudioside *M5*

NMR experiments were performed on a Bruker 500 MHz spectrometer, with the sample dissolved in pyridine-*d*₅. Along with signals from the sample, signals from pyridine-*d*₅ at δ_C 123.5, 135.5, 149.9 ppm and δ_H 7.19, 7.55, 8.71 ppm were observed. ¹H-NMR spectrum of rebaudioside *M5* recorded in pyridine-*d*₅ confirmed the excellent quality of the sample (see Fig. 15a). HSQC (see Fig. 15b) shows the presence of an exomethylene group in the sugar region with a long-range coupling to C-15, observable in the H₂H-COSY (Fig. 15c). Other deep-fielded signals of the quaternary carbons (C-13, C-16 and C-19) are detected by the HMBC (Fig. 15d). Correlation of the signals in the HSQC,

HMBC and ^1H , ^1H -COSY reveal the presence of steviol glycoside with the following aglycone structure:



Correlation of HSQC and HMBC shows the presence six anomeric signals, marked with 1i, 1ii, 1iii, 1iv, 1v, and 1vi. The coupling constant of the anomeric protons of about 8 Hz, the broad signals of their sugar linkage and the NOE-correlations of the anomeric protons allow the identification of these six sugars as β -D-glucopyranosides.

Combined data from HSQC and HMBC reveal the sugar-sugar linkages and sugar-aglycone linkages. The assignment of the sugar sequence was confirmed by using the combination of HSQC-TOCSY (Fig. 15e) and NOESY (Fig. 15f).

Altogether, results from NMR experiments above were used to assign the chemical shifts of the protons and carbons of the structure of rebaudioside *M5* (see Table 8).

Table 8

Chemical shifts of rebaudioside *M5*

Position	δ_C [ppm]		δ_H [ppm]		J [Hz]/ (INT)	HMBC (H -> C)
<i>Aglycone moiety</i>						
1	39.9	<i>t</i>	0.68 1.63	<i>m</i> <i>m</i>		
2	19.4	<i>t</i>	1.36 2.05	<i>m</i> <i>m</i>		
3	37.2	<i>t</i>	1.03 2.80	<i>m</i> <i>m</i>		
4	44.2	<i>s</i>	-			
5	57.1	<i>d</i>	0.95	<i>m</i>		
6	21.7	<i>t</i>	1.95 2.21	<i>m</i> <i>m</i>		
7	41.2	<i>t</i>	1.26 1.51	<i>m</i> <i>m</i>		
8	42.3	<i>s</i>	-			
9	53.6	<i>d</i>	0.85	<i>m</i>		
10	40.3	<i>s</i>	-			
11	19.8	<i>t</i>	1.61 1.63	<i>m</i> <i>m</i>		
12	37.6	<i>t</i>	1.97 2.12	<i>m</i> <i>m</i>		
13	85.9	<i>s</i>	-			
14	43.4	<i>t</i>	1.86 2.50	<i>d</i> <i>d</i>	11.0 11.0	
15	47.6	<i>t</i>	2.00 2.15	<i>d</i> <i>d</i>	16.0 16.0	7, 8, 9, 14
16	153.8	<i>s</i>	-			
17	104.5	<i>t</i>	5.05 5.68	<i>br s</i> <i>br s</i>		13, 15, 16
18	28.4	<i>q</i>	1.40	<i>s</i>	(3H)	3, 4, 5, 19
19	175.4	<i>s</i>	-			
20	16.2	<i>q</i>	1.06	<i>s</i>	(3H)	1, 5, 9, 10


Table 8 (continued)
Chemical shifts of rebaudioside *M5*

Position	δ_C [ppm]		δ_H [ppm]		J [Hz]/ (Int)	HMBC (H $\rightarrow$ C)	NOE (H $\rightarrow$ H)
Sugar moiety							
Sugar I: β -D-Glucopyranoside							
1 ⁱ	97.2	<i>d</i>	5.09	<i>d</i>	7.7	13	3 ⁱ , 5 ⁱ
2 ⁱ	83.9	<i>d</i>	4.00	<i>m</i>			
3 ⁱ	77.5	<i>d</i>	4.29	<i>m</i>			
4 ⁱ	70.7	<i>d</i>	4.19	<i>m</i>			
5 ⁱ	76.5	<i>d</i>	3.79	<i>m</i>			1 ⁱ , 3 ⁱ , 6 ⁱ
6 ⁱ	69.0	<i>t</i>	4.27 4.55	<i>m</i> <i>m</i>			5 ⁱ , 1 ⁱⁱⁱ
Sugar II: β -D-Glucopyranoside							
1 ⁱⁱ	105.9	<i>d</i>	5.18	<i>d</i>	7.8	2 ⁱ	2 ⁱ , 3 ⁱⁱ , 5 ⁱⁱ
2 ⁱⁱ	76.1	<i>d</i>	4.11	<i>m</i>			
3 ⁱⁱ	77.6	<i>d</i>	4.19	<i>m</i>			
4 ⁱⁱ	71.4	<i>d</i>	4.27	<i>m</i>			
5 ⁱⁱ	78.1	<i>d</i>	3.91	<i>m</i>			
6 ⁱⁱ	62.8	<i>t</i>	4.34 4.55	<i>m</i> <i>m</i>			
Sugar III: β -D-Glucopyranoside							
1 ⁱⁱⁱ	105.0	<i>d</i>	5.01	<i>d</i>	8.0	6 ⁱ	6 ⁱ , 3 ⁱⁱⁱ , 5 ⁱⁱⁱ
2 ⁱⁱⁱ	74.9	<i>d</i>	4.02	<i>m</i>			
3 ⁱⁱⁱ	78.0	<i>d</i>	4.20	<i>m</i>			
4 ⁱⁱⁱ	70.8	<i>d</i>	4.16	<i>m</i>			
5 ⁱⁱⁱ	78.3	<i>d</i>	3.92	<i>m</i>			
6 ⁱⁱⁱ	62.4	<i>t</i>	4.42 4.50	<i>m</i> <i>m</i>			
Sugar IV: β -D-Glucopyranoside							
1 ^{iv}	92.8	<i>d</i>	6.25	<i>d</i>	7.8	19	3 ^{iv} , 5 ^{iv}
2 ^{iv}	77.0	<i>d</i>	4.44	<i>m</i>			
3 ^{iv}	88.1	<i>d</i>	4.27	<i>m</i>			
4 ^{iv}	69.0	<i>d</i>	4.11	<i>m</i>			
5 ^{iv}	78.1	<i>d</i>	3.88	<i>m</i>			
6 ^{iv}	61.7	<i>t</i>	4.21 4.34	<i>m</i> <i>m</i>			
Sugar V: β -D-Glucopyranoside							
1 ^v	103.4	<i>d</i>	5.75	<i>d</i>	8.1	2 ^{iv}	2 ^{iv} , 3 ^v , 5 ^v
2 ^v	75.5	<i>d</i>	3.98	<i>m</i>			
3 ^v	78.1	<i>d</i>	4.27	<i>m</i>			
4 ^v	71.2	<i>d</i>	4.12	<i>m</i>			
5 ^v	77.9	<i>d</i>	3.95	<i>m</i>			
6 ^v	62.1	<i>t</i>	4.34 4.50	<i>m</i> <i>m</i>			

Table 8 (continued)
Chemical shifts of rebaudioside *M5*

Position	δ_C [ppm]		δ_H [ppm]		J [Hz]/ (Int)	HMBC (H $\rightarrow$ C)	NOE (H $\rightarrow$ H)
Sugar moiety							
Sugar VI: β -D-Glucopyranoside							
1 ^{vi}	104.4	<i>d</i>	5.28	<i>d</i>	7.8	3 ^{iv}	3 ^{iv} , 3 ^{vi} , 5 ^{vi}
2 ^{vi}	75.1	<i>d</i>	4.00	<i>m</i>			
3 ^{vi}	78.0	<i>d</i>	4.18	<i>m</i>			
4 ^{vi}	71.2	<i>d</i>	4.20	<i>m</i>			
5 ^{vi}	78.1	<i>d</i>	3.99	<i>m</i>			
6 ^{vi}	61.8	<i>t</i>	4.34 4.50	<i>m</i> <i>m</i>			

Correlation of all NMR results indicates rebaudioside *M5* with six β -D-glucoses attached to steviol aglycone, as depicted with the following chemical structure:



LCMS (Fig. 15g and Fig. 15h) analysis of rebaudioside *M5* showed a $[M-H]^-$ ion at m/z 1289.6, in good agreement with the expected molecular formula of $C_{56}H_{90}O_{33}$


(calculated for $[C_{56}H_{89}O_{33}]^-$ monoisotopic ion: 1289.5, error < 0.05%). The MS data confirms that rebaudioside *M5* has a molecular formula of $C_{56}H_{90}O_{33}$. LCMS analysis was performed in the conditions listed in Table 6.

Although the invention and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims. Moreover, the scope of the application is not intended to be limited to the particular embodiments of the invention described in the specification. As one of ordinary skill in the art will readily appreciate from the disclosure of the invention, the compositions, processes, methods, and steps, presently existing or later to be developed that perform substantially the same function or achieve substantially the same result as the corresponding embodiments described herein may be utilized according to the invention.

CLAIMS

We claim:







1. Steviol glycosides I-XLI with the following formulae:













wherein R1 and R2 sugar chains are defined in the following table;







No.	R1	R2
I		
II		
III		







No.	R1	R2
IV		
V		
VI		







No.	R1	R2
VII		
VIII		
IX		







No.	R1	R2
X		
XI		
XII		







No.	R1	R2
XIII		
XIV		







No.	R1	R2
XV		
XVI		
XVII		





No.	R1	R2
XVIII		
XIX		
XX		







No.	R1	R2
XXI		
XXII		
XXIII		





No.	R1	R2
XXIV		
XXV		
XXVI		





No.	R1	R2
XXVII		
XXVIII		
XXIX		

No.	R1	R2
XXX		
XXXI		
XXXII		

No.	R1	R2
XXXIII		
XXXIV		

No.	R1	R2
XXXV		
XXXVI		
XXXVII		

No.	R1	R2
XXXVIII		
XXXIX		

No.	R1	R2
XL		
XLI		

2. A method for producing at least one steviol glycoside of claim 1, comprising the steps of:

- a. providing a starting composition comprising an organic compound with at least one carbon atom;
- b. providing an enzyme preparation or microorganism containing at least one enzyme selected from steviol biosynthesis enzymes, NDP-glucosyltransferases and optionally NDP-glucose recycling enzymes;
- c. contacting the enzyme preparation or microorganism with a medium containing the starting composition to produce a medium comprising at least one steviol glycoside of claim 1.

3. A method for producing at least one steviol glycoside of claim 1, comprising the steps of:

- a. providing a starting composition comprising an organic compound with at least one carbon atom;
- b. providing a biocatalyst comprising at least one enzyme selected from steviol biosynthesis enzymes, NDP-glucosyltransferases and optionally NDP-glucose recycling enzymes;

- c. contacting the biocatalyst with a medium containing the starting composition to produce a medium comprising at least one steviol glycoside of claim 1.
4. The method of claim 2 or 3 further comprising the step of:
 - d. separating at least one steviol glycoside of claim 1 from the medium to provide a highly purified composition of at least one steviol glycoside of claim 1.
5. The method of claim 2, 3 or 4, wherein the starting composition is selected from the group consisting of steviol, steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *D*, rubusoside, steviolbioside *A*, steviolbioside *B*, rebaudioside *B*, stevioside, rebaudioside *G*, stevioside *A*, stevioside *B*, stevioside *C*, rebaudioside *A*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E4*, rebaudioside *E6*, rebaudioside *E3*, rebaudioside *D*, rebaudioside *I*, rebaudioside *AM*, rebaudioside *D7*, rebaudioside *M*, rebaudioside *M4*, rebaudioside *M5*, other steviol glycosides, polyols, carbohydrates, and combinations thereof.
6. The method of claim 2, wherein the microorganism is selected from the group consisting of *E.coli*, *Saccharomyces* sp., *Aspergillus* sp., *Pichia* sp., *Bacillus* sp., and *Yarrowia* sp.
7. The method of claim 3, wherein the biocatalyst is an enzyme, or a cell comprising one or more enzyme, capable of converting the starting composition to at least one steviol glycoside of claim 1.
8. The method of claim 2, wherein the enzyme is selected from the group consisting of a mevalonate (MVA) pathway enzyme, a 2-C-methyl-D-erythritol-4-phosphate pathway (MEP/DOXP) enzyme, geranylgeranyl diphosphate synthase, copalyl diphosphate synthase, kaurene synthase, kaurene oxidase, kaurenoic acid 13-hydroxylase (KAH), steviol synthetase, deoxyxylulose 5-phosphate synthase (DXS), D-1-deoxyxylulose 5-phosphate reductoisomerase (DXR), 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase (CMS), 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (CMK), 4-diphosphocytidyl-2-C-methyl-D-erythritol 2,4- cyclodiphosphate synthase (MCS), 1-hydroxy-2-methyl-2(E)-butenyl 4-diphosphate synthase (HDS), 1-hydroxy-2-methyl-2(E)-butenyl 4-diphosphate reductase (HDR), acetoacetyl-CoA thiolase, truncated HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, mevalonate pyrophosphate decarboxylase, cytochrome P450 reductase, UGT74G1, UGT85C2, UGT91D2, EUGT11, UGTSl2, UGT76G1, UGlyT91C1

or mutant variant thereof having >85% amino-acid sequence identity, >86% amino-acid sequence identity, >87% amino-acid sequence identity, >88% amino-acid sequence identity, >89% amino-acid sequence identity, >90% amino-acid sequence identity, >91% amino-acid sequence identity, >92% amino-acid sequence identity, >93% amino-acid sequence identity, >94% amino-acid sequence identity, >95% amino-acid sequence identity, >96% amino-acid sequence identity, >97% amino-acid sequence identity, >98% amino-acid sequence identity, >99% amino-acid sequence identity.

9. The method of claim 4, wherein the content of at least one steviol glycoside in the highly purified composition of at least one steviol glycoside of claim 1 is greater than about 95% by weight on a dry basis.

10. A consumable product comprising at least one steviol glycoside of claim 1, wherein the product is selected from the group consisting of a food, a beverage, a pharmaceutical composition, a tobacco product, a nutraceutical composition, an oral hygiene composition, and a cosmetic composition.

11. The consumable product of claim 10, wherein the product is selected from the group consisting of beverages; natural juices; refreshing drinks; carbonated soft drinks; diet drinks; zero calorie drinks; reduced calorie drinks and foods; yogurt drinks; instant juices; instant coffee; powdered types of instant beverages; canned products; syrups; fermented soybean paste; soy sauce; vinegar; dressings; mayonnaise; ketchups; curry; soup; instant bouillon; powdered soy sauce; powdered vinegar; types of biscuits; rice biscuit; crackers; bread; chocolates; caramel; candy; chewing gum; jelly; pudding; preserved fruits and vegetables; fresh cream; jam; marmalade; flower paste; powdered milk; ice cream; sorbet; vegetables and fruits packed in bottles; canned and boiled beans; meat and foods boiled in sweetened sauce; agricultural vegetable food products; seafood; ham; sausage; fish ham; fish sausage; fish paste; deep fried fish products; dried seafood products; frozen food products; preserved seaweed; preserved meat; tobacco and medicinal products.

12. The consumable product of claim 10, further comprising at least one additive selected from the group consisting of carbohydrates, polyols, amino acids and their corresponding salts, poly-amino acids and their corresponding salts, sugar acids and their corresponding salts, nucleotides, organic acids, inorganic acids, organic salts including organic acid salts and organic base salts, inorganic salts, bitter compounds, caffeine,

flavorants and flavoring ingredients, astringent compounds, proteins or protein hydrolysates, surfactants, emulsifiers, flavonoids, alcohols, polymers and combinations thereof.

13. The consumable product of claim 10, further comprising at least one functional ingredient selected from the group consisting of saponins, antioxidants, dietary fiber sources, fatty acids, vitamins, glucosamine, minerals, preservatives, hydration agents, probiotics, prebiotics, weight management agents, osteoporosis management agents, phytoestrogens, long chain primary aliphatic saturated alcohols, phytosterols and combinations thereof.

14. The consumable product of claim 10, further comprising a compound selected from the group consisting of steviolmonoside, steviolmonoside *A*, steviolbioside, steviolbioside *A*, steviolbioside *B*, steviolbioside *C*, steviolbioside *D*, steviolbioside *E*, rubusoside, dulcoside *A*, dulcoside *B*, dulcoside *C*, dulcoside *D*, stevioside, stevioside *A*, stevioside *B*, stevioside *C*, stevioside *D*, stevioside *E*, stevioside *E2*, stevioside *F*, stevioside *G*, stevioside *H*, rebaudioside *A*, rebaudioside *A2*, rebaudioside *A3*, rebaudioside *A4*, rebaudioside *B*, rebaudioside *B2*, rebaudioside *C*, rebaudioside *C2*, rebaudioside *C3*, rebaudioside *C4*, rebaudioside *C5*, rebaudioside *C6*, rebaudioside *D*, rebaudioside *D2*, rebaudioside *D3*, rebaudioside *D4*, rebaudioside *D5*, rebaudioside *D6*, rebaudioside *D7*, rebaudioside *D8*, rebaudioside *E*, rebaudioside *E2*, rebaudioside *E3*, rebaudioside *E4*, rebaudioside *E5*, rebaudioside *E6*, rebaudioside *E7*, rebaudioside *F*, rebaudioside *F2*, rebaudioside *F3*, rebaudioside *G*, rebaudioside *H*, rebaudioside *H2*, rebaudioside *H3*, rebaudioside *H4*, rebaudioside *H5*, rebaudioside *H6*, rebaudioside *I*, rebaudioside *I2*, rebaudioside *I3*, rebaudioside *J*, rebaudioside *K*, rebaudioside *K2*, rebaudioside *KA*, rebaudioside *L*, rebaudioside *M*, rebaudioside *M2*, rebaudioside *M3*, rebaudioside *N*, rebaudioside *N2*, rebaudioside *N3*, rebaudioside *N4*, rebaudioside *N5*, rebaudioside *O*, rebaudioside *O2*, rebaudioside *O3*, rebaudioside *O4*, rebaudioside *Q*, rebaudioside *Q2*, rebaudioside *Q3*, rebaudioside *R*, rebaudioside *S*, rebaudioside *T*, rebaudioside *T1*, rebaudioside *U*, rebaudioside *U2*, rebaudioside *V*, rebaudioside *V2*, rebaudioside *V3*, rebaudioside *W*, rebaudioside *W2*, rebaudioside *W3*, rebaudioside *Y*, rebaudioside *Z1*, rebaudioside *Z2*, rebaudioside *AM*, SvG7, NSF-02, Mogroside *V*, siratose, Luo Han Guo, allulose, D-allose, D-tagatose, erythritol, brazzein, neohesperidin dihydrochalcone, glycyrrhizic acid and its salts, thaumatin, perillartine, pernandulcin, mukuroziosides, baiyunoside, phlomisioside-*I*,

dimethyl-hexahydrofluorene-dicarboxylic acid, abrusosides, periandrin, carnosiflosides, cyclocarioside, pterocaryosides, polypodoside *A*, brazilin, hernandulcin, phillodulcin, glycyphyllin, phlorizin, trilobatin, dihydroflavonol, dihydroquercetin-3-acetate, neoastilbin, *trans*-cinnamaldehyde, monatin and its salts, selligueain *A*, hematoxylin, monellin, osladin, pterocaryoside *A*, pterocaryoside *B*, mabinlin, pentadin, miraculin, curculin, neoculin, chlorogenic acid, cynarin, siamenoside, sucralose, potassium acesulfame, aspartame, alitame, saccharin, cyclamate, neotame, dulcin, suosan advantame, gymnemic acid, hodulcin, ziziphin, lactisole, glutamate, aspartic acid, glycine, alanine, threonine, proline, serine, lysine, tryptophan, maltitol, mannitol, sorbitol, lactitol, xylitol, inositol, isomalt, propylene glycol, glycerol, threitol, galactitol, hydrogenated isomaltulose, reduced isomalto-oligosaccharides, reduced xylo-oligosaccharides, reduced gentio-oligosaccharides, reduced maltose syrup, reduced glucose syrup, hydrogenated starch hydrolyzates, polyglycitols, sugar alcohols, L-sugars, L-sorbose, L-arabinose, trehalose, galactose, rhamnose, various cyclodextrins, cyclic oligosaccharides, various types of maltodextrins, dextran, sucrose, glucose, ribulose, fructose, threose, xylose, lyxose, altrose, mannose, idose, lactose, maltose, invert sugar, isotrehalose, neotrehalose, isomaltulose, erythrose, deoxyribose, gulose, talose, erythrulose, xylulose, cellobiose, amylopectin, glucosamine, mannosamine, glucuronic acid, gluconic acid, glucono-lactone, abequose, galactosamine, beet oligosaccharides, isomalto-oligosaccharides (isomaltose, isomaltotriose, panose and the like), xylo-oligosaccharides (xylotriose, xylobiose and the like), xylo-terminated oligosaccharides, gentio-oligosaccharides (gentiobiose, gentiotriose, gentiotetraose and the like), nigero-oligosaccharides, palatinose oligosaccharides, fructooligosaccharides (kestose, nystose and the like), maltotetraol, maltotriol, malto-oligosaccharides (maltotriose, maltotetraose, maltopentaose, maltohexaose, maltoheptaose and the like), starch, inulin, inulo-oligosaccharides, lactulose, melibiose, raffinose, isomerized liquid sugars such as high fructose corn syrups, coupling sugars, soybean oligosaccharides, D-psicose, D-ribose, L-glucose, L-fucose, D-turanose, D-leucrose.

15. A method for enhancing the sweetness of a beverage or food product, comprising a sweetener comprising:

- a. providing a beverage or food product comprising a sweetener; and
- b. adding a sweetness enhancer comprising at least one steviol glycoside of claim 1, wherein at least one steviol glycoside of claim 1 is present in a concentration at or below the sweetness recognition threshold.

16. A method for modifying the flavor of a beverage or food product, comprising
 - a. providing a beverage or food product, and
 - b. adding a composition comprising at least one steviol glycoside of claim 1.
17. A method for suppressing foaming of a beverage or food product, comprising
 - a. providing a beverage or a food product, and
 - b. adding a foam suppressor comprising at least one steviol glycoside of claim 1.




FIG. 1a





FIG. 1b

FIG. 1c







FIG. 1d







FIG. 1f



Rebaudioside 1g

FIG. 1g




FIG. 1h






FIG. 1i








FIG. 11




FIG. 1m




FIG. 1n






FIG. 1a









FIG. 1r

FIG. 1s







FIG. 11

FIG. 2a






FIG. 2c

Rebaudioside 2c

FIG. 2c

SUBSTITUTE SHEET (RULE 26)






FIG. 2e




FIG. 2f




FIG. 25





FIG. 2h

FIG. 2i







FIG. 2j

FIG. 2k

Rebaudioside 2k

FIG. 2k






FIG. 2m




FIG. 2n




FIG. 20





FIG. 2







FIG. 2f






FIG. 3a




FIG. 3b

FIG. 4a








FIG. 4c














FIG. 4j




Rebaudioside M

UGTS12, or
EUGT11, or
UGT91D2



Rebaudioside 1n











FIG. 4I




















FIG. 5a







FIG. 5b



64/176











FIG. 5f










FIG. 5j








FIG. 5k












FIG. 5p





FIG. 5q






FIG. 5s




FIG. 5t




FIG. 6a




FIG. 6b






FIG. 6c








FIG. 6f




FIG. 6g




FIG. 6h




FIG. 6i




FIG. 6j





FIG. 6k






FIG. 6m




FIG. 6n






FIG. 60





98/176

FIG. 6q








FIG. 6r









103/176

FIG. 7b




FIG. 8a





FIG. 8b



106/176

FIG. 8c




FIG. 8d




FIG. 8e





FIG. 8f






FIG. 8g

111/176

FIG. 8h




FIG. 8i




FIG. 8j





FIG. 8k






FIG. 8m




FIG. 8n




FIG. 8o






FIG. 8p



120/176

FIG. 8q



121/176

FIG. 8r




FIG. 8s




FIG. 8t




FIG. 9a




FIG. 9b




FIG. 10a





FIG. 10b



128/176

FIG. 10c





FIG. 10d






FIG. 10f





FIG. 10g



133/176

FIG. 10h




FIG. 10i




FIG. 10j




FIG. 10k




FIG. 101




FIG. 10m





FIG. 10n








FIG. 10o

FIG. 10p




142/176

FIG. 10q



143/176

FIG. 10r






FIG. 10t




FIG. 11a





FIG. 11b









FIG. 12a













153/176


FIG. 13a

























161/176

















168/176






FIG. 14h


169/176


FIG. 15a





170/176














FIG. 15g




FIG. 15h

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2020/018460

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C07H 1/00; C07H 15/256; C12P 19/56 (2020.01)

CPC - A23L 27/36; C07H 1/00; C07H 15/256; C12P 19/56 (2020.05)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

see Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

see Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

see Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	CN 105838759 A (NANJING NUOYUN BIOLOGICAL TECHNOLOGY CO LTD) 10 August 2016 (10.08.2016) see machine translation and original	1-3, 6 ----- 8, 10-17
Y	WO 2018/213290 A1 (PURECIRCLE USA INC) 22 November 2018 (22.11.2018) entire document	8, 10-16
Y	US 2017/0303566 A1 (SUNTORY BEVERAGE & FOOD LIMITED) 26 October 2017 (26.10.2017) entire document	17
P, X	WO 2019/178471 A1 (PURECIRCLE USA INC) 19 September 2019 (19.09.2019) entire document	1-3, 6, 8, 10-17

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

03 June 2020

Date of mailing of the international search report

08 JUL 2020

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Blaine R. Copenheaver

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2020/018460

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 4, 5, 7, 9
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See extra sheet(s).

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-3, 6, 8, 10-17

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2020/018460

Continued from Box No. III Observations where unity of invention is lacking

Claims 1-3, 6, 8, and 10-17 have been analyzed subject to the restriction that the claims read on steviol glycoside I with the following formula, wherein R1 and R2 sugar chains are defined as the first entry in the table of claim 1.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2020/018460

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees need to be paid.

Group I+: claims 1-3, 6, 8, and 10-17 are drawn to steviol glycosides I-XLI, methods for producing at least one steviol glycoside thereof, consumable products thereof, methods for enhancing the sweetness of a beverage or food product thereof, methods for modifying the flavor of a beverage or food product thereof, and methods for suppressing foaming of a beverage or food product thereof.

The first invention of Group I+ is restricted to steviol glycoside I with the following formula, wherein R1 and R2 sugar chains are defined as the first entry in the table of claim 1; methods for producing at least one steviol glycoside thereof; consumable products thereof; methods for enhancing the sweetness of a beverage or food product thereof; methods for modifying the flavor of a beverage or food product thereof; and methods for suppressing foaming of a beverage or food product thereof. It is believed that claims 1-3, 6, 8, and 10-17 read on this first named invention and thus these claims will be searched without fee to the extent that they read on the above embodiment.

Applicant is invited to elect additional formula(e) for each additional compound to be searched in a specific combination by paying an additional fee for each set of election. Each additional elected formula(e) requires the selection of a single definition for each compound variable. An exemplary election would be steviol glycoside II with the following formula, wherein R1 and R2 sugar chains are defined as the second entry in the table of claim 1; methods for producing at least one steviol glycoside thereof; consumable products thereof; methods for enhancing the sweetness of a beverage or food product thereof; methods for modifying the flavor of a beverage or food product thereof; and methods for suppressing foaming of a beverage or food product thereof. Additional formula(e) will be searched upon the payment of additional fees. Applicants must specify the claims that read on any additional elected inventions. Applicants must further indicate, if applicable, the claims which read on the first named invention if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched/examined.

The inventions listed in Groups I+ do not relate to a single general inventive concept under PCT Rule 13.1, because under PCT Rule 13.2 they lack the same or corresponding special technical features for the following reasons:

The Groups I+ formulae do not share a significant structural element requiring the selection of alternatives for the compound variables R1 and R2 and accordingly these groups lack unity a priori.

Additionally, even if Groups I+ were considered to share the technical features of steviol glycosides I-XLI with the following core structure; a method for producing at least one steviol glycoside, comprising the steps of: a. providing a starting composition comprising an organic compound with at least one carbon atom; b. providing an enzyme preparation or microorganism containing at least one enzyme selected from steviol biosynthesis enzymes, NDP-glucosyltransferases and optionally NDP-glucose recycling enzymes; c. contacting the enzyme preparation or microorganism with a medium containing the starting composition to produce a medium comprising at least one steviol glycoside; a method for producing at least one steviol glycoside, comprising the steps of: a. providing a starting composition comprising an organic compound with at least one carbon atom; b. providing a biocatalyst comprising at least one enzyme selected from steviol biosynthesis enzymes, NDP-glucosyltransferases and optionally NDP-glucose recycling enzymes; c. contacting the biocatalyst with a medium containing the starting composition to produce a medium comprising at least one steviol glycoside; a consumable product comprising at least one steviol glycoside, wherein the product is selected from the group consisting of a food, a beverage, a pharmaceutical composition, a tobacco product, a nutraceutical composition, an oral hygiene composition, and a cosmetic composition; a method for enhancing the sweetness of a beverage or food product, comprising a sweetener comprising: a. providing a beverage or food product comprising a sweetener; and b. adding a sweetness enhancer comprising at least one steviol glycoside wherein at least one steviol glycoside is present in a concentration at or below the sweetness recognition threshold; a method for modifying the flavor of a beverage or food product, comprising a. providing a beverage or food product, and b. adding a composition comprising at least one steviol glycoside; and a method for suppressing foaming of a beverage or food product, comprising a. providing a beverage or a food product, and b. adding a foam suppressor comprising at least one steviol glycoside, these shared technical features do not represent a contribution over the prior art as disclosed by WO 2018/213290 A1 to Purecircle USA Inc. and US 2017/0303566 A1 to Suntory Beverage & Food Limited.

WO 2018/213290 A1 to Purecircle USA Inc. teaches steviol glycosides I-XLI with the following core structure (Abstract, rebaudiosides M); a method for producing at least one steviol glycoside (Claim 1), comprising the steps of: a. providing a starting composition comprising an organic compound with at least one carbon atom (Claim 1); b. providing an enzyme preparation or microorganism containing at least one enzyme selected from steviol biosynthesis enzymes, NDP-glucosyltransferases and optionally NDP-glucose recycling enzymes (Claim 1); c. contacting the enzyme preparation or microorganism with a medium containing the starting composition to produce a medium comprising at least one steviol glycoside (Claim 1); a consumable product (Claim 10) comprising at least one steviol glycoside, wherein the product is selected from the group consisting of a food, a beverage, a pharmaceutical composition, a tobacco product, a nutraceutical composition, an oral hygiene composition, and a cosmetic composition (Claim 10); a method for enhancing the sweetness of a beverage or food product (Claim 19), comprising a sweetener comprising: a. providing a beverage or food product comprising a sweetener (Claim 19); and b. adding a sweetness enhancer comprising at least one steviol glycoside wherein at least one steviol glycoside is present in a concentration at or below the sweetness recognition threshold (Claim 19); and a method for modifying the flavor of a beverage or food product (Claim 19), comprising a. providing a beverage or food product, and b. adding a composition comprising at least one steviol glycoside (Claim 19).

US 2017/0303566 A1 to Suntory Beverage & Food Limited teaches a method for suppressing foaming of a beverage or food product (Claim 8), comprising a. providing a beverage or a food product (Claim 8), and b. adding a foam suppressor comprising at least one steviol glycoside (Claim 8).

The inventions listed in Groups I+ therefore lack unity under Rule 13 because they do not share a same or corresponding special technical feature.